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ZUSAMMENFASSUNG    
 
Malaria ist eine der wichtigsten Infektionskrankheiten und betrifft weltweit mehrere 
Millionen Menschen. Eine wirksame Impfung gegen Malaria ist momentan noch nicht 
verfügbar, wäre aber eine wertvolle Ergänzung zu den bereits bestehenden Malaria-
Kontroll-Strategien. Obwohl davon ausgegangen wird, dass Antikörper (AK) die 
natürlich erworbene partielle Immunität gegen den komplexen Malariaerreger 
vermitteln, bleiben der genaue AK-vermittelte Mechanismus bzw. die immunologischen 
Zusammenhänge, die zum Schutz gegen schwere Malaria führen, unklar. 
Standardisierte Versuche zur AK-Messung fehlen ebenfalls, weshalb keine Einigkeit 
darüber besteht, welche Methode am besten geeignet ist, um Antikörper gegen Malaria 
zu quantifizieren, zu beschreiben und zu interpretieren. In diesem Zusammenhang ist 
es das Ziel dieser Dissertation robuste standardisierte Verfahren für Messungen der 
Plasmodium-spezifischen AK einzuführen und die AK-Avidität als einen potenziellen 
Marker des impfvermittelten Schutzes gegen Malaria zu untersuchen.  
Im ersten Teil wird eine neue zytometriebasierte Immunfluoreszenzmethode, bei der 
ganze Parasiten verwendet werden, beschrieben. Auf diese Weise wird versucht  den 
Schutz vor Malaria mit der AK-Antwort zu erklären. Ein neu entwickelter 
Subtraktionsalgorithmus (overlap substraction algorithm (OSA)) ermöglicht die 
untersucherunabhängige Analyse der Daten. Im Rahmen der Dissertation wurden 
Messungen an Proben von Kindern und Erwachsenen, die Teilnehmer in einer 
klinischen Studie Phase I für den Malaria-Impfkandidaten GMZ2 waren, vor (D0) und 
nach (D84) der Impfung durchgeführt. Die Ergebnisse zeigen, dass Kinder, die mit der 
höchsten GMZ2-Dosis (100µg) geimpft wurden, einen 1,33-fachen Anstieg des Anteils 
fluoreszierender Zellen (percent positive fluorescent cells (PPFC; p=0,003)) an Tag 84 
im Vergleich zu Tag 0 aufweisen. An Tag 84 konnte ein impfinduzierter verstärkender 
Effekt auf die bereits existierende anti-parasitäre Immunität (1,23-facher Anstieg in der 
mittleren Fluoreszenzintensität (mean fluorescent intensity (MFI), p=0,03) in semi-
immunen Erwachsenen nachgewiesen werden. 
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Im zweiten Teil dieser Arbeit wurde eine modifizierte ELISA-basierende Methode 
implementiert, um den Aviditäts-Index (AI) von anti-Circumsporozoite Protein (CSP) AK 
von zwei unterschiedlichen Immunisierungsschemata (0-1-2 Monate und 0-1-7 Monate) 
mit dem Malariaimpfstoff RTS,S in einer Kohorte von gesunden afrikanischen 
Säuglingen zu untersuchen. Die Analysen zeigen, dass die Avidität der anti-CSP AK 
nach RTS,S Impfung wie erwartet ansteigt, die absolute AI die Impfeffektivität aber nicht 
vorhersagt. Die AIs der AK waren in beiden Immunisierungsplänen vergleichbar. 
Hervorzuheben ist, dass die Änderung der anti-CSP AK Titer (dCSP) und des Aviditäts-
Indexes (dAI) zwischen der zweiten und der dritten Immunisierung mit 77% und 54% 
Reduktion des Risikos zur Entwicklung einer Malaria, assoziiert ist. Die Entwicklung der 
Avidität von CSP-spezifischen AK sollte in weiteren Studien untersucht werden, um zu 
sehen ob sie ein Marker für die Wirksamkeit von RTS,S ist.  
Zusammenfassend lässt sich sagen, dass standardisierte neue Instrumente entwickelt 
wurden, um parasitenspezifische AK-Antworten zu untersuchen und die detaillierte 
Erforschung von anti-CSP AK-Avidität erweitert das momentane Verständnis der AK-
vermittelten Immunität gegen Malaria. Diese Untersuchungen können als Basis für 
zukünftige Arbeiten zur AK-basierter Immunität für Malaria dienen und zur Entwicklung 
und der Evaluation von funktionellen anti-Malaria Impfungen der zweiten Generation 
beitragen. 
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SUMMARY  
Malaria remains a major public health scourge affecting millions of people worldwide. 
An effective antimalarial vaccine is currently lacking and if available would add to other 
malaria control strategies. Although antibodies (Abs) are thought to mediate protective 
immunity to malaria, the exact Ab-mediated mechanisms or immunological correlates of 
protection against the complex plasmodial parasite remain unclear. Standardized 
assays for Ab measurement are also lacking and therefore no consensus exists on the 
best approach to quantitate, report and interpret antimalarial Abs. In an attempt to 
address some of these hurdles, this dissertation aims to implement robust standardized 
assays for measurements of Plasmodium-specific Abs and to investigate Ab avidity as a 
potential surrogate marker of vaccine-mediated protection against malaria. 
 
In the first study, a novel cytometric based immunofluorescence assay technique is 
described that improves the detection of anti-plasmodial Abs using whole parasites and 
may be suitable for investigating Ab-based correlates of protection. An overlap 
subtraction algorithm (OSA) developed in parallel eliminates the investigator-dependent 
effects and thus facilitates the data analysis process. The workflow was applied to pre-
(D0) and post-vaccination (D84) clinical samples from children and adult participants of 
Phase 1 trials of the malaria vaccine GMZ2. The results demonstrate that children 
vaccinated with the highest GMZ2 dose (100µg) showed a 1.33-fold increase in percent 
positive fluorescent cells (PPFC; p=0.003) on D84 compared to D0. Meanwhile, on D84, 
a vaccine-induced boosting effect of pre-existing anti-parasitic immunity (1.23-fold 
increase in mean fluorescent intensity; MFI, p=0.03) was observed in semi-immune 
adults. 
 
In a second study, a modified ELISA-based method to assess the avidity index (AI) of 
anti-circumsporozoite protein (CSP) Abs elicited by two immunization (0-1-2 month and 
0-1-7 month) schedules with the malaria vaccine RTS,S in a cohort of healthy African 
infants was used. The analyses revealed that the avidity maturation of anti-CSP Abs 
following RTS,S vaccination occurred as expected, although absolute AI did not predict 
vaccine efficacy. The AIs of Abs were found to be similar in both immunization 
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schemes. Interestingly, the change in anti-CSP Ab titer (dCSP) and avidity index (dAI) 
between second and third immunization was associated with 77% and 54% risk-
reduction to develop clinical disease, respectively. Avidity maturation of vaccine-specific 
Abs deserves further investigation as surrogate marker of protective efficacy.  
 
Together, standardized new tools for investigating parasite-specific Ab responses were 
developed and the detailed investigation of anti-CSP Ab avidity expands contemporary 
understanding of Ab-mediated indicators of protective immunity against malaria. These 
studies might serve as a basis for further work on Ab-based immunity to malaria and 
contribute to the development and evaluation of functional second-generation 
antimalarial vaccines.  
 
7 
 
LIST OF PAPERS 
This doctoral dissertation is based on the following two original papers, which will be 
referred to by their Roman numerals: 
 
I. Ajua A, Engleitner T, Esen M, Theisen M, Issifou S, Mordmüller B. A flow 
cytometry-based workflow for detection and quantification of anti-plasmodial 
antibodies in vaccinated and naturally exposed individuals.  
Malaria Journal 2012; 11:367. 
 
II. Ajua A, Lell B, Agnandji ST, Asante KP, Owusu-Agyei S, Mwangoka G, Mpina M, 
Salim N, Tanner M, Abdulla S, Vekemans J, Jongert V, Lievens M, Cambron P, 
Ockenhouse CF, Kremsner PG and Mordmüller B. The effect of immunization 
schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy 
and anti-circumsporozoite protein antibody avidity in African infants.  
Malaria Journal 2015; 14:72. 
 
 
Contributions to other publications not included in this dissertation: 
 
III. Mamo H, Esen M, Ajua A, Theisen M, Mordmüller B, and Petros B. Humoral 
immune response to Plasmodium falciparum vaccine candidate GMZ2 and its 
components in populations naturally exposed to seasonal malaria in Ethiopia. 
Malaria Journal 2013; 12:51. 
 
IV. Esen M, Forster J, Ajua A, Spänkuch I, Paparoupa M, Mordmüller B, and 
Kremsner PG.  Effect  of  IL-15  on  IgG  versus  IgE  antibody-secreting  cells  
in  vitro.   
Journal of Immunological Methods 2012; 375(1-2): 7-13. 
 
 
8 
 
LIST OF ABBREVIATIONS 
Abs  Antibodies  
ADCI  Antibody-dependent cellular inhibition 
AI  Avidity index 
AMA  Apical membrane antigen 
AS01E  Adjuvant system associated with RTS,S malaria vaccine candidate 
ASCs  Antibody secreting cells  
CD  Cluster of differentiation  
CHMI  Controlled human malaria infection  
CSP  Circumsporozoite protein 
DCs  Dendritic cells 
DDT  Dichlorodiphenyltrichloroethane 
EBA  Erythrocyte-binding protein  
ELISA  Enzyme-linked immunosorbent assay 
EPI  Expanded program on immunization  
FMP   Falciparum malaria protein  
GIA  Growth inhibition assay 
GLURP Glutamate rich protein 
GMZ2  Blood-stage malaria vaccine candidate 
HBV  Hepatitis B virus  
HPV  Human papillomavirus 
IFA  Immunofluorescence assay  
IFN  Interferon  
Ig  Immunoglobulin 
IL  Interleukin 
ITNs  Insecticides-treated mosquito nets 
ME-TRAP Multiple-epitope–thrombospondin-related adhesion protein  
MFI  Mean fluorescent intensity 
MSP  Merozoite surface protein 
NHP  Non-human primates 
NK  Natural killer  
9 
 
OSA  Overlap subtraction algorithm 
PfRH5 Plasmodium falciparum reticulocyte-binding protein homologue 5  
PfSPZ  Plasmodium falciparum sporozoite  
PPFC  Percent of positive fluorescence cells 
PPRs  Pattern recognition receptors 
RBC  Red blood cell 
RTS,S Pre-erythrocytic stage malaria vaccine candidate 
TCM  Central memory T cells 
TEM  Effector memory T cells 
Th  T helper 
TLRs  Toll-like receptors  
Tregs  Regulatory T cells 
TNF  Tumor necrosis factor   
WHO  World Health Organization 
10 
 
 
1. GENERAL INTRODUCTION  
 
1.1 Malaria: causative agent, epidemiology and control 
Malaria is an infectious disease caused by obligate intracellular protozoal parasites 
which belong to the genus Plasmodium. The parasite is transmitted from human to 
human by infected female Anopheles mosquitoes. Currently, five plasmodial species 
are able to infect humans, namely P. falciparum, P. vivax, P. ovale, P. malariae, and P. 
knowlesi. In tropical Africa, P. falciparum is the most common species and is 
responsible for nearly 225 million cases of malaria and almost a million deaths annually, 
mostly among children below 5 years of age and pregnant women [1]. Meanwhile, in 
Asia and Latin American countries most of the remaining malaria cases are caused by 
P. vivax. The temperate regions (USA, Canada and Europe) that were also endemic for 
malaria are now free of malaria today due to successful implementation of malaria 
control including insecticide programs using dichlorodiphenyltrichloroethane (DDT) 
(Figure 1) [2].  
 
The continued large-scale implementation of malaria control strategies in Africa, such 
as insecticides-treated mosquito nets (ITNs) and highly effective artemisinin-based 
therapies, has led to a significant reduction in malaria case incidence (reviewed in [3]). 
Nevertheless, malaria transmission is difficult to control in most endemic countries, 
partly due to the rise of insecticide and antimalarial drug resistance, even to the highly 
effective artemisinin-based therapies [4, 5]. This underscores the urgent need to 
develop more reliable interventional tools, including efficacious antimalarial vaccines to 
curb the disease.  
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Figure 1. Intensity of malaria in countries with ongoing malaria transmission, 2013.  
Source: WHO World Malaria Report, 2014 [2]. 
 
1.2 Life cycle of Plasmodium spp. 
 
The malaria life cycle is complex with different parasite stages developing in both the 
human and mosquito hosts (Figure 2). The cycle begins following the mosquito’s 
injection of saliva containing infective sporozoites into human skin. The sporozoites exit 
the skin tissues and travel through the bloodstream and ultimately invade liver cells, 
multiply and differentiate asexually as exoerythrocytic stage parasites (liver-stage). 
During development in hepatocytes, the host presents no clinical symptoms of the 
disease.  
 
Depending on the parasite species, maturation of liver-stages takes five to ten days. 
One infected liver cell releases thousands of merozoites into the blood stream that 
invade erythrocytes, grow, multiply and ultimately lead to the infection of up to ten new 
erythrocytes (blood-stage). This asexual blood stage results in a feed-forward loop with 
exponential growth of the parasite population if it is not controlled by immunity, 
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metabolic restriction or antimalarial treatment. It is therefore responsible for the 
symptoms and pathology of malaria. The erythrocytic cycle follows a variable periodic 
pattern: one day for P. knowlesi; two days for P. falciparum, P. ovale and P. vivax or 
three days in the case of P. malariae (reviewed in [3]).  
 
During the erythrocytic cycle, some merozoites do not multiply but instead differentiate 
into the male and female gametocytes. When taken up by the mosquito during feeding, 
these sexual forms may fertilize within the mosquito’s midgut to form a zygote, which 
matures to become an ookinete and subsequently the oocyst, which ultimately releases 
sporozoites, the infective form of the parasite. The sporozoites migrate to the 
mosquito’s salivary glands and become available to infect the next host, thus 
completing the parasite’s transmission cycle. 
 
Figure 2. Life cycle of Plasmodium spp. in the human and mosquito hosts. Numbers in 
square boxes represent crude estimates of malaria parasites in the respective stage.  
Reprinted with permission from Elsevier Limited. 
Source: White et al. 2014 [3]. 
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1.3 Immunity to malaria 
During malaria parasite development in the vertebrate host, many antigens produced by 
the different parasite stages are capable of provoking the host’s innate, humoral and 
cellular immune responses. Successful activation of innate, humoral and cellular 
immune mechanisms can induce a complex network of defense machineries that lead 
to the release of immune mediators that can limit further growth and development of the 
parasite (reviewed in [6]) as described below or result in immunopathology including 
sepsis-like syndromes and other life-threatening complications. 
 
1.3.1 Innate immunity to malaria 
The innate immune system provides the first-line of defense against Plasmodium 
infections after the induction of non-specific immune effector cells that are capable of 
targeting and damaging the malaria parasite (reviewed in [6]). Pre-existing cells of the 
innate immune system are able to sense infection using pattern recognition receptors 
(PRRs), such as toll-like receptors (TLRs) expressed in various cell types including 
dendritic cells (DCs) [7, 8]. Once sporozoites are injected into the host’s skin, they could 
be detected and engulfed by DCs, monocytes, macrophages, natural killer (NK) cells or 
other cells of the innate immune system present near the inoculation site. The 
plasmodial antigens are processed and presented to T cells in association with MHC 
class II molecules [9, 10], which may result in proliferation of antigen-specific T cells. A 
successful immune response (i.e. a response that results in clearance of the pathogen) 
depends on multiple factors, including the strength of stimulation, type of infected cells 
and quality of the antigen recognition. Apart from resolving the infection, some immune 
cells are instrumental in fine-tuning the magnitude and quality of the ensuing antibody- 
or cellular-mediated immune responses [10-12].  
Due to the large antigen load blood-stage parasites can initiate strong innate immune 
responses via the generation of interferon (IFN)-γ, tumor necrosis factor (TNF)-α and 
interleukin (IL)-12 by different cell types (reviewed in [6]). However, studies in animal 
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models report that the parasite’s liver-stages could equally induce potent innate immune 
responses mediated by IFN-γ secretion [13] when stimulated appropriately. 
 
1.3.2 Antibody-mediated immunity to malaria  
The humoral immune response against asexual blood stage parasites is marked by the 
generation of a large repertoire of Immunoglobulin G (IgG) secreting cells. So far, the 
role of IgM, IgA, and IgE is not well described [14]. However, antibodies are important in 
mediating protective immunity to malaria, as has been clearly shown in passive transfer 
experiments where hyper-immune serum [15] and purified total IgG [16, 17] were used 
to control blood-stage clinical malaria. Similar studies in non-human primates (NHPs) 
confirmed that protective antibodies are critical for clearance of asexual blood-stage 
malaria infections [18]. Additional studies further demonstrated that transfer of 
antibodies to the circumsporozoite protein (CSP) of P. falciparum can protect mice from 
subsequent sporozoite challenge [19-21]. 
 
The IgG-mediated protection is largely dependent on the breadth of specific cytophilic 
IgG1 and IgG3 antibodies (reviewed in [22]). Though parasite-specific IgE antibodies 
also increase during malaria infections, it is not clearly known how they contribute to 
antimalarial immunity [14].  In general, antibodies exert protective functions by inhibiting 
hepatocytes invasion (reviewed in [6]), merozoite invasion of erythrocytes [23], blocking 
parasite adherence and sequestration to host’s tissues to avoid clearance in the spleen 
[24], and elimination of parasite-infected red cells by phagocytosis [25]. Antibody-
dependent cellular inhibition (ADCI) has been proposed as a mechanism by which 
antibodies to glutamate rich protein (GLURP) and merozoite surface protein (MSP)-3 
may confer protection [26]. Although IgG1, IgG3, tumor necrosis factor (TNF) and other 
molecules have been reported to play a role in ADCI [27], the IgG3 antibodies against 
an MSP3-derived peptide (LR55) have recently been identified as the major inducer of 
ADCI activity [28]. The relative contribution of the different antibody-mediated activities 
to control malaria following naturally acquired infection and vaccine-induced immunity 
are not known. 
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1.3.3 Cell-mediated immunity to malaria  
As described earlier, during the pre-erythrocytic phase of development, neutralizing 
antibodies can block hepatocyte invasion by sporozoites. Subsequently, the parasite 
develops within liver cells, a compartment that is difficult to access by antibodies. 
Hence, parasite-infected liver cells seem to be targeted by CD8+ T cells via secretion of 
the cytolytic factors perforin and granzyme B (reviewed in [29]). This could explain why 
higher levels of granzyme B-producing CD8 T cells have been associated with 
protection from clinical malaria following challenge of human volunteers with sporozoite-
infected mosquitoes [30]. 
 
Apart from CD8+ T cells, specific CD4+ T cells are also associated with a successful 
immune response against pre-erythrocytic stages. For example, a recent study reported 
the strongest association of protection with cytotoxic CD4 T cells in humans following 
sporozoites challenge via the bites of the mosquito vector [30]. Four main subsets have 
been reported based on their cytokine patterns, namely, T helpers (Th) 1, Th2, Th17 
and Tregs. Th1 cells secrete inflammatory cytokines such as IL-2, IFN-γ, and TNF-α, 
which activate macrophages and other cells to produce their own mediators. Th2 cells 
produce mainly IL-4, IL-5 and IL-13, which regulate the humoral immune response by 
activating B cells to differentiate into antibody secreting cells (ASCs) and produce 
antibodies. In addition, CD4+ T cells potentiate and sustain CD8+ T cells responses as 
well as regulate the cytokine produced by Th1 and Th2 cells to equilibrium levels 
(reviewed in [31]), a balance that is likely to determine the immunological control of 
malaria parasites. The initial pro-inflammatory response following malaria infection is 
crucial for the control of parasite replication as well as clearance of infected red blood 
cells (RBCs). A lack of an effective pro-inflammatory response could lead to unrestricted 
proliferation of the parasite. Conversely, failure to regulate the inflammatory response 
may result in the development of severe malaria (reviewed in [32]). In addition to the 
cell-mediated responses described, antibody-mediated anti-parasitic activity is crucial 
for the final control and clearance of malaria parasites (reviewed in [6]). 
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1.3.4 Naturally acquired immunity and immunological memory to malaria 
It is generally believed that naturally-acquired immunity to malaria is short-lived and 
requires repeated exposure to parasite antigens to generate and sustain an effective 
memory response. Immunological memory, which builds up over time is orchestrated by 
memory T and B cells. These cells are known to rapidly proliferate and differentiate into 
T and B effector cells upon pathogen encounter, where they play key roles in protective 
immunity to malaria. For instance, accumulated long-lived memory B cells rapidly 
secrete specific high-affinity and high-titered antibodies to the most frequently 
encountered parasite antigens that are instrumental for control of blood-stage parasite 
load (reviewed in [6, 33]).  
 
Notwithstanding, memory responses to plasmodial antigens seem not to be very 
effective and likely attributable to the seasonal nature of malaria transmission in 
endemic areas, the complexity of the pathogen and its life cycle and the constant 
exposure of humans to persistent or intermittent malaria infection (reviewed in [34]). 
Other challenges include the fact that naturally-induced responses are mostly antigen- 
and stage-specific, the difficulty of inducing high amounts of antibodies of the required 
quality and the development of parasites in different intracellular host’s systems shields 
them from recognition and attack by antibody-mediated mechanisms further limit the 
generation of potent long-term memory responses to malaria (reviewed in [6]). 
 
The provision of long-lasting protection is important for successful immunization 
programmes and many vaccines are optimized to generate a robust, long-lived 
immunologic memory. In this light, successful vaccines, such as those against yellow 
fever, smallpox, polio, tetanus toxoid and measles are prime examples as they provide 
up to lifelong protection against re-infection through antibody- and cell-mediated 
mechanisms ([35], reviewed in [36]).  
Although no vaccine is currently licensed for use against malaria, an efficient 
antimalarial vaccine may need to induce robust and strong immune responses in order 
to confer protection against clinical malaria [37]. Antibodies alone may not suffice to 
achieve high levels of protective efficacy. Hence, the induction of potent vaccine-
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specific T cell responses may also be crucial to confer protective immunity to malaria 
(reviewed in [6]), especially when the pre-erythrocytic stages of the plasmodial life-cycle 
is targeted.  
 
1.4 Malaria vaccine development 
Throughout history, vaccination has been one of the most successful strategies of 
controlling human and animal diseases. Until today, all successful vaccines were 
developed empirically, with limited understanding of how they induce protective 
immunity. This makes it very difficult nowadays to apply the same approach to design 
highly efficacious vaccines for emerging diseases [38]. The same is true for malaria 
vaccine development, where so far no reliable protective mechanisms or immune 
correlates of protection have been identified. Compared with some viruses and bacteria 
that are controllable through vaccination, malaria parasites are much larger and 
complex, as the parasite contains approximately 5000 diverse proteins, some of them 
highly polymorphic. This complicates the task of developing highly protective subunit 
malaria vaccines and further explains why until date no malaria vaccine is available for 
clinical use (reviewed in [6, 39, 40]). Notwithstanding, intensive research is ongoing to 
develop stage-specific vaccines targeting the three major parasite developmental 
stages; sporozoites and infected hepatocytes (pre-erythrocytic stage), merozoites and 
infected erythrocytes (asexual blood stage), as well as gametocytes (Figure 3). The 
results so far are promising, as a good number of candidates described below are 
currently in clinical development (Figure 4). The present work will focus on the RTS,S 
and GMZ2 vaccine candidates since the author took part in their development.   
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Figure 3. Malaria vaccine approaches: aims and required immune responses. TEM, 
effector memory T cells; TCM, central memory T cells.  
Reprinted with permission from Nature Publishing Group. 
Source: Riley and Stewart, 2013 ([6]). 
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Figure 4. Global malaria vaccine development pipeline.  
Source: WHO, 2015 [41]. 
 
1.4.1 Pre-erythrocytic stage vaccines 
As depicted in Figure 3, the pre-erythrocytic stage vaccines are designed to block 
infection of liver cells by sporozoites as well as prevent completion of their development 
within hepatocytes, if infection occurs [6]. Targeting these parasite forms is 
advantageous but also difficult as only few sporozoites are normally transmitted to 
humans when the vector takes a blood meal [42]. To be efficacious, a pre-erythrocytic 
malaria vaccine must entirely block transition of parasites to the asexual blood stage 
parasites. If successful, this would also prevent transmission and hence could be used 
in malaria elimination programs [39]. On the other side, only one successful passage 
through the liver suffices to cause disease since the mechanism of pre-erythrocytic 
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immunity is different from the naturally acquired immunity against asexual blood stage 
parasites (reviewed in [43]). The feasibility of a pre-erythrocytic vaccine stem from 
studies where experimental vaccines based on radiation-attenuated Plasmodium 
sporozoites conferred sterile protection against malaria in different host systems (for 
example, [44-46]). Parasite-specific neutralizing antibodies as well as T cells (CD4+ and 
CD8+ T cells) have been identified as major players mediating protection to the pre-
erythrocytic parasite-stages in experimental animals ([47]; reviewed in [6, 48, 49]). 
 
More than 10 pre-erythrocytic vaccine candidates have progressed through preclinical 
studies and are being tested in clinical trials (reviewed in [50]; Figure 4). The most 
successful candidate so far is RTS,S. It targets an immunodominant fragment of P. 
falciparum circumsporozoite protein (CSP), which is composed of the central repeat 
region (R) that contains the B-cell and T-cell epitopes (T) of CSP. In RTS,S CSP is 
fused to the hepatitis B virus (HBV) surface (S) antigen and co-expressed in 
Saccharomyces cerevisiae with an additional HBV S-antigen, hence the name “RTS,S” 
(Figure 5). This means that RTS,S is a combination vaccine against malaria and 
hepatitis B. RTS,S is adjuvanted with the liposome-based Adjuvant System (AS) 01, 
which contains the immunostimulants monophosphoryl lipid A and a purified Quillaja 
saponaria saponin (QS-21) (reviewed in [51, 52]).  
 
After many years of clinical development and extensive testing of RTS,S in populations 
living in different transmission settings, the vaccine was found to be safe, well tolerated 
and efficacious. It consistently showed moderate protective efficacy against infection 
and clinical disease over one year (for example, reviewed in [6, 39, 40, 50-52]). These 
findings constituted the driving force behind the implementation of large scale phase III 
efficacy trials in seven African countries [39]. The results from such trials have shown 
that RTS,S is able to reduce the rates of clinical as well as severe malaria by about 30% 
in African infants 6-12 weeks old [53]. Earlier findings from the same trials in children of 
aged 5–17 months reported that the protective efficacies of RTS,S against both clinical 
and severe malaria vaccine ranged from 50 to 56% [54].  With protective efficacy of 30-
50%, RTS,S may be licensed and deployed as the world’s first generation malaria 
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vaccine for use in sub-Saharan Africa where the disease burden remains relatively high 
(reviewed in [39]). Notwithstanding, research is on-going to improve the efficacy of 
RTS,S by including additional antigens in order to create a multi-stage, multi-antigen 
RTS,S-based vaccine [55].  
 
            
 
Figure 5: The CSP of P. falciparum and the protein region incorporated into the RTS,S 
vaccine.   
Reprinted with permission from the American Society for Clinical Investigation. 
Source: Crompton  et al. 2010 [52]. 
 
1.4.2 Blood-stage vaccines 
The scientific rationale for developing blood-stage vaccines stem from the fact that 
clinical illness, complications and fatality associated with malaria occurs during blood-
stage infection. As such, an effective blood-stage vaccine would have the greatest 
impact by reducing malaria parasitemia, clinical symptoms and complications, hence 
such vaccines are intended for use in reducing morbidity due to malaria in endemic 
areas [56].  
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This vaccination approach is based on the concept that following repeated malaria 
attacks, persons living in malaria-endemic countries often develop acquired immunity 
that often targets blood-stage antigens. Infected persons are therefore able to control 
parasite density to below fever thresholds [57]. It may therefore be possible to mimic 
and accelerate the development of anti-disease immunity through a blood-stage malaria 
vaccine [52].  
Several blood-stage vaccines are composed of merozoite surface-derived antigens 
(reviewed in [58]) that lead to the production of antibodies that block invasion and 
replication of merozoites within red cells (Figure 3). Such neutralizing antibodies may 
also target parasite-infected red cells preventing their adherence to different host 
tissues and reducing their numbers to levels that do not cause clinical disease or death 
(reviewed in [6, 39, 40]). 
 
Clinical evaluation of previous candidates, such as merozoite surface protein (MSP)1-, 
MSP2- and apical membrane antigen (AMA)1-based vaccines, showed no protective 
efficacy, although some showed signs of allele-specific protection (reviewed in [6]). As a 
consequence, further clinical development of these candidates slowed down (reviewed 
in [40, 59]). The lack of MSP1-based vaccine efficacy may be due to genetic diversity of 
MSP1 protein (reviewed in [39]) and for the AMA1-based vaccine candidate, efficacy 
was mostly strain-specific [60]. Currently, a few other promising candidates (Figure 4) 
are being evaluated in field trials, including the erythrocyte-binding protein 175 
(EBA175), MSP3181-276, and GMZ2 (reviewed in [59]).  
With advances in knowledge and technology, new antigens are being discovered and 
further developed as blood-stage vaccines candidates [61, 62]. One such antigen is the 
P. falciparum reticulocyte-binding protein homologue 5 (PfRH5). PfRH5, a merozoite 
protein located in the neck of rhoptries has been identified as essential for erythrocyte 
invasion [63]. PfRH5-induced inhibitory antibodies have been shown to block the 
invasion of RBCs in animal models as well protect NHPs against clinical disease 
following challenge with a heterologous P. falciparum strain [62, 64].  
Although the antigen is not a major target of naturally acquired antibodies to P. 
falciparum, naturally acquired anti-PfRH5 antibodies have been shown to predict 
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protection from clinical malaria [65]. Thus, PfRRH5 constitute an attractive blood-stage 
vaccine candidate [62], and two PfRH5–based vaccine candidates (ChAd63 RH5 and 
MVA RH5) are currently undergoing human Phase 1a clinical trials [66]. 
 
Among those, GMZ2 is the most advanced candidate. It is a combination vaccine 
composed of the N-terminal region of glutamate rich protein (GLURP27–500) (non-repeat 
R0 region and major B-cell epitope) and the conserved C-terminal fragment of MSP3212-
380 and expressed in Lactococcus lactis [67].  
The discovery and further clinical development of GMZ2 was based on the ability of 
MSP3 and GLURP to induce high titers functional antibodies assessed by antibody 
growth inhibition assay (GIA) and ADCI [26, 68]. GIA measures the ability of purified 
IgG or serum antibodies to inhibit the invasion and subsequent growth of malaria 
parasites in human red cells in vitro. On the other hand, the ADCI assesses the 
antibody-dependent cellular activity of monocytes against malaria parasites (reviewed in 
[69]). 
In pre-clinical studies, GMZ2 induced broader antibodies to both GLURP and MSP3 
than co-administration of the antigens alone or a mix of both. The protective effects of 
anti-GMZ2 IgG antibodies was demonstrated by in vitro parasite-growth inhibition [67]. 
In further studies in NHPs, the vaccine was found to induce partial protection against P. 
falciparum [70]. These findings showed that GMZ2 could be a valuable malaria vaccine 
candidate and pave the way for its further clinical development [67, 70]. 
In Phase I trials of GMZ2 adjuvanted with aluminium hydroxide, high levels of vaccine 
antigen-induced antibodies and GMZ2-specific memory B-cells were detected in 
malaria-naive Germans as well as in malaria-exposed adults and children. The vaccine 
was found to be safe and well tolerated. These results supported further clinical testing 
of GMZ2 in a much larger population (reviewed in [59]). The recently completed multi-
center Phase IIb efficacy trials enrolled almost 2000 children aged 1-5 years in study 
sites in Burkina Faso, Gabon, Ghana and Uganda.  
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1.4.3 Transmission blocking vaccines 
As the name suggests, such vaccines are designed to target the gametocytes, gametes 
and ookinetes, preventing them from maturing, infecting and developing in the mosquito 
vector. Such candidates are not meant to provide individual level protection, as in the 
case of pre-erythrocytic and blood-stage vaccines, but instead to stop malaria 
transmission at the community level. The hope is that in the long-term this approach 
could be helpful in the elimination and even eradication of malaria from certain areas 
(reviewed in [71]). Knowledge about how this type of vaccine induces immunity is very 
limited, but it is widely believed that antibodies, cytokines and complement taken up by 
the vector in the course of feeding on blood hamper the development of sexual stages 
into infective sporozoites (reviewed in [6, 40]). 
 
The development of malaria transmission blocking vaccines proceeds at a slower pace 
compared with the other types of malaria vaccines. However, two major gametocyte-
specific surface antigens, Pfs48/45 and Pfs230, and two ookinete-specific surface coat 
proteins, Pfs25 (P. falciparum) and Pvs25 (P. vivax), constitute the main focus of anti-
transmission vaccines (reviewed in [72]). So far, the leading candidates (Pfs25 and 
Pfvs25), formulated in Montanide ISA 51, have been tested in Phase I trials. Safety 
concerns led to modification of the Pfs25 vaccine antigen, as well as replacement of the 
adjuvant. Use of the reformulated Pfs25 conjugated to recombinant Pseudomonas 
aeruginosa ExoProtein A (Pfs25-EPA) and adjuvanted with alhydrogel has given 
satisfactory results in Phase 1a trials (reviewed in [59]). 
 
1.4.4 Multi-stage, multi-antigen and whole parasite vaccines 
Most current candidate vaccines under development aim to target just one stage of the 
parasite's life cycle. Considering the vast number of antigens expressed by the four 
human parasite stages (sporozoites, liver stage, merozoites and gametes), it is 
proposed that next-generation malaria vaccines be designed to have wider coverage by 
targeting multiple parasite developmental stages (reviewed in [73, 74]), and as such 
could induce multi-immune responses to many different parasite antigens that may 
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provide better protection [75].  The greatest challenge of this strategy is to identify and 
choose the optimal antigen combination that would induce the most robust and desired 
immune responses. However, adding other components (FMP1; falciparum malaria 
protein 1) to the most clinically advanced malaria vaccine (RTS,S/AS02A) did not show 
an improvement in the level of protection [55]. Other multi-component vaccines, for 
example the multiple-epitope–thrombospondin-related adhesion protein (ME-TRAP) and 
polyepitope DNA-based vaccines have also been developed and are currently been 
tested in field trials (reviewed in [59]).  
 
Apart from multistage and multi-antigen vaccines, developing a whole parasite vaccine 
based on attenuated sporozoites is been actively pursued. The approach had proved to 
be highly successful since the 1970s [76]. Whole organism vaccines are so far the only 
vaccines that have reached >90% protective efficacy against malaria in humans [44, 77, 
78]. The downside of this approach is the need for hundreds of infected mosquitoes for 
vaccination. Sanaria Inc., an U.S. based company has recently developed methods to 
purify and cryopreserve fully infectious and attenuated P. falciparum sporozoites 
(PfSPZ). Vaccination by intravenous injection of radiation-attenuated PfSPZ (PfSPZ 
Vaccine) led up to 100% protective efficacy in a small number of human volunteers 
receiving controlled human malaria infection (CHMI) [79], which further confirms the 
potency of this vaccination concept. However, the issue of the need of intravenous 
administration, scalability and maintenance of cold chain are critical issues that still may 
limit the large-scale applicability of this strategy for immunization of infants, should the 
PfSPZ vaccine becomes adopted in future as a vaccine against malaria.  
 
 
1.5 Antibodies as correlate or surrogate markers of protection  
An immune correlate of protection as defined by Plotkin [36] is an immune response 
closely related to protection or that provides protection. Immune correlates are 
considered to be of prime importance during efficacy trials of vaccine candidates 
(reviewed in [36]).  
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In circumstances where the exact correlates of protective immunity are unknown, 
unavailable or hard to measure, useful surrogate or substitute markers - mostly serum 
antibodies - are measured mostly by enzyme-linked immunosorbent assay (ELISA) and 
associated with vaccine-induced protection in clinical studies (reviewed in [36]). Plotkin 
[80] further defined a surrogate marker as an immune response that substitutes for the 
true immunologic correlate of protection, which may be unknown or not easily 
measurable. In general, most successful vaccines are known to induce high levels of 
antigen-specific neutralizing antibodies of defined protective threshold which serve as 
biomarkers of protection against disease (reviewed in [38, 80]).   
 
A direct cause-and-effect relationship between vaccine-induced antimalarial antibodies 
and protection from malaria disease is yet to be established. As a consequence, there 
are currently no validated immunological markers or correlates of protection against 
malaria, either by naturally-acquired anti-disease immunity or elicited by the most 
advanced malaria vaccine candidate RTS,S [55]. Studies have shown that the induction 
of robust CSP-specific antibodies by the RTS,S vaccine is associated with better 
protection from clinical malaria (reviewed in [6, 81]), although the data are inconsistent.  
 
In the case of blood-stage vaccines where antibodies are considered as the effective 
agent or crucial for protection against disease, two promising candidates (AMA-1 and 
FMP-1) both failed to provide a meaningful protective immunity [82, 83]. Nevertheless, 
certain neutralizing antibodies subclasses (IgG1 and IgG3) specific for some blood-
stage vaccine antigens have been associated with protection against malaria disease 
[84]. As such, malaria-specific antibody responses are frequently considered as 
surrogate marker of protection to malaria disease [85].  
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2. AIMS OF THE PRESENT WORK 
 
Our research team has over the years been involved in the clinical development of 
different malaria vaccine candidates, including the most advanced pre-erythrocytic 
vaccine (RTS,S) and blood-stage vaccine (GMZ2) candidates. With the aim to expand 
current knowledge of vaccine immunogenicity and contribute to the search for antibody-
based correlates of protection against malaria, I worked on serum samples collected 
from three clinical trials of the afore-mentioned vaccine candidates to characterize the 
development of antibody-based immune responses in different populations of vaccinees 
presented in this dissertation.  
In order to achieve these goals, two separate but related immunological studies were 
performed. First, a cytometry-based immunoassay was set up to standardize the 
quantification of anti-plasmodial IgG antibodies in the serum of GMZ2-vaccinees. 
Second, the avidity index (AI) of antibodies to the CSP repeats induced by RTS,S was 
evaluated in vaccine recipients. 
The specific objectives of the work presented in this dissertation are as follows:  
 To develop and implement a quantitative flow cytometry based assay for high 
throughput measurement of anti-plasmodial and vaccine-induced IgG 
antibodies to whole malaria parasite antigens (Paper I). 
 
 To evaluate the change in the avidity of anti-CSP antibodies over time in a cohort 
of infants who underwent two separate immunization schedules of RTS,S and 
explore the effect of anti-CSP IgG avidity on RTS,S vaccine efficacy (Paper 
II). 
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3. RESULTS  
 
A summary of the results obtained in each of the papers is presented here. Reference is 
made to the tables and figures in the different publications. 
 
3.1 Paper I 
 
 
A flow cytometry-based workflow for detection and quantification of anti-
plasmodial antibodies in vaccinated and naturally exposed individuals 
 
Anthony Ajua, Thomas Engleitner, Meral Esen, Michael Theisen, Saidou Issifou and 
Benjamin Mordmüller.  
Malaria Journal 2012; 11:367. 
 
Antibodies are known to play an important role in anti-malarial immunity but the exact 
antibody-mediated correlates of protection remain elusive. Highly standardized assays 
that may allow comparability of antibody measurements are also lacking and so the best 
way to measure, report and interpret antimalarial antibody responses is unknown. 
In this study, the standard microscopy-based immunofluorescence assay (IFA) was 
transformed into a standardized, investigator- and bias-free, high throughput-amenable 
cytometry-based assay to assess antibody reactivity against whole parasites. 
The novel cytometry-based assay was validated using semi-immune serum samples 
from Gabonese adults (Figure 2, Figure 3 – Paper I) and applied to sera from adult and 
pediatric participants of two GMZ2 Phase Ib trials.  
Baseline anti-plasmodial antibodies and the effect of vaccination on the anti-GMZ2 
antibody response were evaluated. Upon vaccination, children vaccinated with the 
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highest GMZ2 dose (100µg) showed a 1.33-fold increase in percent positive fluorescent 
cells (PPFC; p=0.003) on D84 compared to D0 (Figure 7 – Paper I). Adults showed a 
boost of pre-existing anti-parasitic antibodies resulting in improved parasite recognition 
(increased MFI; 1.23-fold change; p=0.03) (Table 3 – Paper I). 
During analysis, we observed that available statistical approaches (e.g. model-based 
gating algorithms) to analyze flow cytometry data were performing worse than bias-
prone manual gating strategies (Table 1, Figure 4, Figure 5, Table 2 – Paper I). A new 
method for data-driven gating, the overlap subtraction algorithm (OSA), was developed 
and tested against other strategies. OSA-derived results correlated well with those 
derived by expert manual gating and showed improved characteristics of performance 
compared to other frequently used strategies when applied to data of the novel assay 
(Table 1, Figure 4, Figure 5, Table 2, Figure 6 – Paper I). 
Taken together, standardized new tools are presented that could be useful for 
characterizing antibody-mediated immune responses and identifying vaccine-induced 
correlates of protection against malaria. 
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3.2 Paper II 
 
 
The effect of immunization schedule with the malaria vaccine candidate 
RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody 
avidity in African infants 
Anthony Ajua, Bertrand Lell, Selidji Todagbe Agnandji, Kwaku Poku Asante, Seth 
Owusu-Agyei, Grace Mwangoka, Maxmilliam Mpina, Nahya Salim, Marcel Tanner, 
Salim Abdulla,  Johan Vekemans, Erik Jongert, Marc Lievens, Pierre Cambron, Chris F. 
Ockenhouse, Peter G. Kremsner and Benjamin Mordmüller. 
Malaria Journal 2015; 14:72. 
 
RTS,S is known to induce antibodies against the P. falciparum circumsporozoite protein 
(CSP). While higher levels of RTS,S-induced anti-CSP antibodies have been associated 
with protection against infection and episodes of clinical malaria, it is unknown if anti-
CSP antibody avidity (strength of antibody binding) predicts  RTS,S-induced protection. 
In this second study, anti-CSP antibody avidity was measured during two different 
three-injection vaccination schedules to assess if it predicts vaccine efficacy in infants 
immunized with RTS,S. The clinical Phase II trial included one arm receiving the 
standard regimen (0-1-2 month) and the other arm received a delayed third dose (0-1-7 
month) vaccination schedule of RTS,S/AS01E [86, 87]. 
The findings indicated that post dose 3, the antibody concentration and absolute AI 
were similar (p>0.05) in both immunization schedules (Figure 2 – Paper II). Meanwhile, 
an increase in AI (dAI) between the second and third vaccine doses was observed in 
the two different schedules, though the increment was modestly higher for the extended 
vaccination schedule (7.1-fold increase) compared to the standard schedule (4.2-fold 
increase) (Figure 3 – Paper II).  
AI, dAI and change in median anti-CSP titers (dCSP) were evaluated as biomarkers for 
RTS,S-mediated protection. It was observed that AI after the third dose was not 
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associated with a significant reduction in the risk of developing malaria. Furthermore, 
the dCSP and dAI datasets were divided on the median and volunteers classified as 
“high” and “low” responders. Compared with the “low-dCSP” group, classification as 
“high-dCSP” responder was associated with a significant risk reduction (77%) to 
develop clinical malaria. Similarly, classification as “high-dAI” group member was 
associated with a 54% risk reduction (Figure 4 – Paper II).    
This study suggests that an increase in anti-CSP IgG concentration and avidity between 
second and third vaccine injection is associated with a strong risk-reduction for malaria 
after immunization. 
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4. GENERAL DISCUSSION AND CONCLUSIONS 
 
Antibodies elicited through pathogen infection or by vaccination constitute an essential 
component of the humoral immune response in humans and anti-parasitic antibodies 
play an important role in protective immunity to malaria [15-19, 21]. Despite this fact, the 
exact antibody responses, their targets and functional activities that are required to 
mediate protection are largely unknown [85]. Moreover, there are no reliable means to 
adequately distinguish protective from non-protective antibodies [88]. These intellectual 
and experimental challenges might contribute to the multiple unsuccessful attempts to 
develop a highly potent antimalarial vaccine [89]. A clear understanding of the 
mechanisms of protective immunity and identification of immune correlates of protection 
against malaria could be a way to revolutionize the development and introduction of 
vaccines with greater efficacy [6, 89]. Such knowledge may further pave the way for 
detailed quantitative evaluation of current and next-generation vaccines as well as serve 
as a measure for estimating efficacy, duration of protection or immunological memory 
following vaccination without the need of large and expensive trials in vulnerable 
populations with the clinical endpoint malaria [90]. 
 
As malaria-specific antibodies may change following infection [88] or after immunization, 
accurate quantification becomes critical for the assessment of immunogenicity and 
investigation of antibody correlates [91]. However, there is currently no consensus on 
the choice of assay(s) that could be employed to measure antibody responses or 
investigate potential markers of protection [6, 92-94]. The development and 
implementation of standardized methods will facilitate the accurate and reproducible 
detection of specific vaccine-induced immune responses and guide the vaccine 
development process [93, 95]. Moreover, the use of robust standardized assays for 
antibodies assessment would allow better comparison of vaccine immune responses 
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especially in the context of multicenter clinical studies and might aid in the identification 
of novel correlates of protection [93].  
 
Most vaccine candidates under clinical development are evaluated for immunogenicity 
using IgG-based assays, such as ELISA and the indirect immunofluorescence assay 
(IFA), as they are considered good markers for predicting protective malaria immunity 
[93]. Although these assays are rapid and easy to perform, they have important 
limitations. For instance, coating of antigen onto a solid support, as is normally done in 
the ELISA-based system may alter the antigen structure and hence affect its reactivity 
[92, 96]. Moreover, the technique only measures the antibody response to single 
antigens at a time and thus requires larger volumes of serum [97], when antibody 
responses to multiple antigens are being tested. On the other hand, the IFA is an 
important immune-epidemiological tool [98, 99] and also has great value in vaccine-
induced antibody functionality studies [98, 100], considering that whole parasite antigen 
can be used for antibody detection. The downside of IFAs are their low throughput, 
dependence on the investigator and poor standardization, which limits their widespread 
applicability in biological and clinical research [101]. Each of the two studies presented 
in this dissertation addresses a major gap in knowledge that affects malaria research in 
general and malaria vaccine development in particular.   
 
In a first study, we developed and validated a new high throughput flow cytometry-
based IFA assay and tool for rapid and reliable measurement and analysis of anti-
plasmodial antibodies in human serum [102]. This new workflow was applied to 
evaluate the effect of vaccination on antibody responses using residual serum samples 
and clinical data from participants who completed two Phase 1 clinical trials of GMZ2 
candidate malaria vaccine [103, 104]. 
For antibody detection, matured P. falciparum schizonts served as an antigen source for 
performing the assay. Following cultivation, whole schizont parasites were fixed using a 
combination of paraformaldehyde and glutaraldehyde as described [105], which better 
preserve the antigen structure [106] and might facilitate the occurrence of an anti-
parasitic reaction. Employing fixed and intact parasites makes it possible that large 
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number of samples such as those from immune-epidemiology and multicenter clinical 
studies can be consistently analyzed over an extended time period, especially when a 
loader-equipped flow cytometer is used. A data analytical tool (OSA), developed and 
incorporated into the assay setup reduced bias and facilitated analysis of large flow 
cytometric datasets.  
 
Recent findings indicate that the host’s previous encounters with malaria antigens could 
affect the evaluation of vaccine-induced effects [85]. Similarly, maternally-derived pre-
existing antibodies have been shown to interfere with the development of antibody 
responses following immunization of mice with an MSP1-based vaccine [107]. Our 
analyses revealed an increase in vaccine-induced anti-plasmodial antibodies response 
(increase in PPFC; percent of positive fluorescent cells) in children with no prior or very 
limited pre-existing malaria immunity. In contrast, a vaccine-mediated boosting of pre-
existing anti-parasitic immune response (increase in MFI; mean fluorescent intensity) 
was observed in the semi-immune adults. The pattern of reactivity showed that the 
assay is able to capture the level and time of exposure to malaria by comparing 
baseline values of antibodies in malaria-exposed children to adults. This could help 
analysis and interpretation of immunogenicity data following vaccination in highly 
endemic regions because it allows incorporation of previous exposure into the analysis 
[85]. 
Moreover, reliable quantification of the cumulative antibody responses to all accessible 
whole parasite antigens, instead of using single parasite proteins may better predict in 
vivo protection [91]. Our assay may be very useful in this regard, as it potentially 
measures both naturally-acquired and vaccine-induced anti-plasmodial antibodies to 
parasite antigens in populations with varying degree of immunity.  
 
Efficacy studies of the RTS,S vaccine candidate have shown that the induction of high 
titers of CSP-specific antibodies partially predicts the protective efficacy of the vaccine 
[87, 108, 109]. This implies that apart from antibody amounts, other characteristics of 
antibody, such as isotype, subclass, functional properties, ability of vaccine-induced 
antibodies to bind to intact parasites, or affinity and/or avidity of antibodies, may be 
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important determinants of antibody function ([110], reviewed in [111]). It is very difficult 
to systematically investigate all these parameters in the same study, due to the 
restricted sample volumes available for immunological studies. However, high titers and 
avidity antibodies have been proposed as the leading antibody-based mechanisms 
(Figure 3, page 18) by which vaccine-induced protective immunity to malaria can be 
achieved by the different vaccine types (reviewed in [6]).  
Interestingly, antibody avidity (AI), a marker of antibody quality, has also been identified 
as an important marker of efficacy for some licensed vaccines ([112, 113], reviewed in 
[80]). So far, antibody avidity has not been extensively investigated in the framework of 
malaria vaccine development ([92]), and only very few biological studies have assessed 
the avidity of antibodies in humans [114-117] and in a mouse model of malaria [118]. 
Together, these studies have suggested that high avidity of naturally-acquired 
antibodies to blood-stage antigens could predict antimalarial immunity and protection 
from clinical disease. In terms of pre-erythrocytic stage antigens, studies in mice have 
associated high anti-CSP antibody affinity with protection from subsequent sporozoite 
challenge [21, 119].   
Although these findings may be encouraging, there are no data from clinical studies of 
malaria vaccine candidates. Therefore, I chose to explore as part of this dissertation the 
avidity of antibodies induced by the CSP-based candidate vaccine RTS,S for a number 
of reasons. First, the number of sporozoites deposited into the human skin is typically 
relatively small (median: 15 sporozoites) [42]. Moreover, sporozoites are known to be 
poorly immunogenic, as they only circulate for a brief period of time (reviewed in [6]) 
and migrate from the mosquito’s injection site on the skin to the liver in less than 15 
minutes [120]. As such, sporozoites may be less prone to exposure and damage by 
antibodies. Hence, the availability of high amounts of sporozoite-specific antibodies 
during the pre-erythrocytic infection phase (reviewed in [121]), combined with the high 
speed and strength of antibody binding to sporozoites may be critical to confer 
protection.  
 
In the second study, we evaluated the change in antibody avidity over time and 
explored the contribution of AI to the protective efficacy induced by two immunization 
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schedules of the RTS,S vaccine. For this first investigation of its kind, we used serum 
samples and clinical data from multicenter Phase 2b trials [86, 87] that evaluated the 
safety, immunogenicity and clinical efficacy of RTS,S when co-administered with 
vaccines routinely administered through the World Health Organization’s Expanded 
Program on Immunization (EPI). Antibody responses induced by the vaccine had been 
assessed by a standard ELISA technique [122]. The same assay was adapted for the 
measurement of the AI of anti-CSP antibodies in the current study. In terms of vaccine 
outcome, both the 0-1-2 month and the 0-1-7 month vaccination schedules reportedly 
showed comparable vaccine efficacy. In addition, one year after the third vaccine dose, 
high vaccine-induced anti-CSP antibody titers were associated with a significant 
reduction (48%) in the risk to develop clinical disease [87]. This therefore offered an 
excellent opportunity for us to attempt investigations of possible biomarkers to predict 
vaccination outcome. 
 
A number of factors, such as the nature and dose of vaccine antigen, certain adjuvants 
and carrier proteins as well as the interval between vaccine doses, can modulate the 
avidity of antibodies ([123, 124], reviewed in [125]). Interestingly, the analyses revealed 
that after the second and third vaccine doses, AI was similar between the two vaccine 
schedules. This implies that delaying the third vaccine dose does not improve the 
avidity of antibodies strongly as would be expected if longer interval between 
vaccination favored the induction of long-lived anti-CSP antibodies [121] and affinity 
maturation of antibodies (reviewed in [125]). Our observation is nevertheless notable as 
it supports the adoption of the 0-1-2 month vaccination schedule of RTS,S for further 
clinical evaluation, which can be easily integrated into the EPI vaccine schedules used 
in developing countries. A similar study recently reported that spacing either the second 
(0-6 month) or third (0-1-6 month) dose of the human papillomavirus (HPV) vaccine 
does not seem to increase the magnitude of antibody avidity in vaccine recipients [126]. 
As expected, avidity increased in the two vaccine groups between the second and last 
vaccine dose. This reflects the sequential acquisition of somatic mutations and hence 
affinity maturation of B cells in the germinal centers following repeated immunization 
with the same vaccine antigen [127].  
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Although antibody avidity has been proposed as an important correlate of protective 
efficacy for several vaccine types [112, 113, 128], we observed no significant 
association between the avidity of anti-CSP antibody and RTS,S-mediated protective 
efficacy, even after adjustment for possible confounding variables as site, schedule and 
anti-CSP antibody concentrations. This could mean that avidity is not an important 
determinant of RTS,S vaccine efficacy but it should be noted that analysis of the effect 
of anti-CSP antibody avidity on protective efficacy was purely exploratory and not 
prospectively planned in the original study. We were nevertheless able to demonstrate 
in this study that the increase of antibody titer (dCSP) and avidity (dAI) between the 
second and third vaccine doses greater than the median were significantly associated 
with 77% and 54% reduction in the risk to develop clinical malaria, respectively.  
 
 
CONCLUSIONS 
 
In the first part of this dissertation, the development and validation of a novel, non-
biased, cytometry-based immunoassay that improves the detection of anti-plasmodial 
antibodies in malaria-exposed and non-exposed populations is described. The new 
approach can therefore be reliably used to reproducibly assess possible antibody-
mediated correlates or surrogates of protection against clinical malaria.  
In the second study, affinity maturation of anti-CSP antibodies elicited by the RTS,S 
candidate vaccine in infants was investigated in samples from a trial designed to 
measure clinical vaccine efficacy. Avidity after three RTS,S doses did not predict 
protection, but an increase of avidity between second and third RTS,S injection greater 
than the median was associated with a 54% risk-reduction to develop malaria. 
Additional studies are proposed to further explore the suitability of anti-CSP antibody 
avidity kinetics as a surrogate marker of RTS,S-mediated protection. 
Taken together, the studies presented in this dissertation provide a reliable mean of 
quantifying antimalarial antibodies and advance current understanding of antibody-
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mediated immunity to malaria and constitute an important step towards the 
development of highly effective antimalarial vaccines. 
 
 
5. PERSONAL CONTRIBUTIONS 
 
My personal contributions to the two papers presented in this thesis are as follows: 
Paper I: (Malaria Journal Published): A flow cytometry-based workflow for detection 
and quantification of anti-plasmodial antibodies in vaccinated and naturally exposed 
individuals.  
 Contributed to the study design,  
 Established the flow cytometry-based IFA,  
 Performed the laboratory experiments,   
 Analyzed and interpreted the datasets, and  
 Drafted and reviewed the manuscript for publication. 
 
Paper II: (Malaria Journal Published): The effect of immunization schedule with the 
malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-
circumsporozoite protein antibody avidity in African infants. 
 Contributed to the study conception,  
 Organized, cleaned, analyzed and interpreted the data, and 
 Prepared, revised and approved manuscript for publication. 
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Background
Malaria is a major cause of morbidity and mortality in
endemic countries with African children carrying the
major burden of the disease. An efficacious malaria vac-
cine would be a cost-effective and easy-to-implement
intervention to complement current control strategies,
but until today no malaria vaccine is registered for rou-
tine use [1], although one product – RTS,S/AS01 – has
shown promising results in a clinical phase III study [2].
In contrast to vaccines containing pre-erythrocytic anti-
gens, such as RTS,S, vaccines directed against the asex-
ual blood stage are thought to act mainly through
antibodies (Abs). Hence, it is hypothesized that anti-
plasmodial Ab concentrations similar to those acquired
upon natural exposure are required to attain semi-
immunity, a type of non-sterile but robust immunity
that protects from clinical complications and excessive
parasite replication [1,3]. The main evidence for the role
of Abs in semi-immunity comes from studies where
purified Abs from African malaria-immune adults were
successfully used to treat non-immune malaria patients
[4,5] within Africa or, as an extension of this, in South-
East Asia [5]. The mechanisms, properties, and specifici-
ties of Abs that mediate protection in malaria, however,
remain unknown [3].
During clinical development of the malaria vaccine
candidate GMZ2 [6-8], it was noted that current assays
to monitor immunogenicity and pre-existing immunity
to malaria with intact parasites are bias-prone and diffi-
cult to standardize. Conventionally, most approaches are
based on enzyme-linked immunosorbent assay (ELISA)
using recombinant proteins or synthetic peptides as bait
antigen [9]. These could differ from their corresponding
native parasite counter-parts in their folding and post-
translational modifications, potentially altering the target
protein’s antigenic properties [3]. In addition, the degree
of parasite antigen exposure to the immune system (e.g.
the effects of localization in protein complexes or orga-
nelles) may be crucial for an effective anti-parasitic reac-
tion or as a correlate for successful vaccination. This
becomes even more important as second-generation,
multi-subunit and whole cell vaccines enter clinical de-
velopment [10]. As such, the use of microscopic
immunofluorescent antibody assay (IFA) to study Ab
concentrations against total parasite proteins expressed
in mature blood stage schizonts and merozoites using
native parasites [9,11] may provide important insights
into the Ab-mediated anti-plasmodial immune response.
Microscopic IFA however, has many setbacks; quantifi-
cation is done by determination of titers and quality
control remains problematic due to poor assay
standardization and potential investigator bias. Addition-
ally, the assay is not scalable and, therefore, investigation
of larger cohorts proves prohibitive [12]. On the other
side, in skillful hands, microscopic IFA is highly sensitive
and specific and provides information about the ability
of vaccine-induced Abs to bind to native parasite mole-
cules [9]. This being known, a scalable, sensitive, repro-
ducible, and quantitative assay based on flow cytometry,
a well-established and automatable technology, which is
widely available in developing countries [13], was pro-
posed to improve microscopy-based assays and allow for
high throughput measurements [14-16]. A major draw-
back of this approach is that flow cytometry data are
routinely analysed by manual gating, which is potentially
biased and inconsistent [15]. To overcome these chal-
lenges, a data-driven algorithm was developed to auto-
matically analyse flow cytometric data and a novel
workflow for a medium-throughput, sensitive, and reli-
able flow cytometry-based immunoassay for the detec-
tion and quantification of anti-plasmodial antibodies in
human serum is presented.
Methods
Study populations and serum samples
Serum samples from Day 0 (before vaccination) and Day
84 (4 weeks after the last of three vaccine administra-
tions) were collected from two clinical trials of GMZ2.
Details of the volunteers and vaccination schedules are
described elsewhere [7,8]. In brief, two double-blind,
randomized phase Ib clinical trials of GMZ2 were per-
formed in Lambaréné, Gabon; one enrolled adults [8],
the other pre-school children [7]. The trial involving
healthy Gabonese adults took place between July 2007
and August 2008. Twenty participants received 100 μg
GMZ2 adjuvanted with aluminium hydroxide (alum)
subcutaneously on Days 0, 28 and 56, whereas the 20
participants in the control group received rabies vaccine
intramuscularly at the same time points (Days 0, 28, and
56). The pediatric trial took place from September 2008
to October 2009 and involved 30 healthy pre-school
children aged 1 to 5 years. The children received three
doses of either rabies control vaccine (n = 10), 30 μg
GMZ2 (n = 10) or 100 μg GMZ2 (n = 10). The 3 doses
were administered one month apart (Days 0, 28 and 56)
by intramuscular injection.
Both studies were reviewed by the regional ethics
committee (Comité d‘Ethique Régional Indépendant de
Lambaréné; CERIL) and followed Good Clinical Practice
guidelines as defined by the International Conference on
Harmonization. All studies were conducted according
to the principles of the Declaration of Helsinki in its
5th revision.
Plasmodium falciparum culture, synchronization and
enrichment for late stages
The laboratory-adapted P. falciparum strain 3D7A,
obtained from the Malaria Research and Reference
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Reagent Resource (ATCC, Virginia, USA) was cultured
in complete medium (RPMI 1640, 25 mM HEPES,
2.4 mM L-glutamine, 50 μg/mL gentamicin and 0.5% w/v
Albumax). Confirmatory experiments were done using
the P. falciparum strain Dd2 obtained from the same
source. All cultures were maintained at 37°C in an atmos-
phere of 5% CO2 and 5% O2, with daily changes of
medium at 5% haematocrit and dilution with red blood
cells when the parasitaemia exceeded 5%.
Parasite cultures were synchronized at early ring stage
by treatment with 5% D-sorbitol (Sigma, St. Louis, USA)
for 10 min at 37°C. Isolation of synchronized P. falcip-
arum parasites (late trophozoite and schizont) was per-
formed using LD-MACS magnetic columns (Miltenyi
Biotec, Gladbach, Germany), as described previously, at
a parasitaemia of about 5% [17]. Following enrichment,
the purity of the parasite preparation was verified by
light microscopy and by flow cytometry after DNA stain-
ing with Hoechst 33342. In later experiments, Vybrant
DyeCycle violet stain (Invitrogen, Germany) replaced
Hoechst 33342.
Flow cytometry-based immunofluorescence assay
to detect anti-plasmodial antibodies
Preparation of parasites for cytometry was based on
a previously described fixation protocol [18]. Briefly,
P. falciparum culture enriched for late developmental
parasite stages were washed once in phosphate buffered
saline (PBS) and fixed by incubation in a combination
of PBS with 4% EM grade paraformaldehyde (Merck,
Germany) and 0.0075% EM grade glutaraldehyde
(Sigma-Aldrich, Germany) for 30 min. Fixed cells were
washed again in PBS and permeabilized for 10 min
in PBS/0.1% Triton-X-100 (TX100) (Sigma-Aldrich,
Germany). After another PBS wash step, free aldehyde
groups were reduced by incubating cells for 10 min
in PBS with 0.1 mg/ml sodium borohydride (Merck,
Germany). The preparation was washed again with PBS
and cells blocked in PBS/3% BSA. The cells were counted
using a haemocytometer (Neubauer–counting chamber)
and the pellet reconstituted in PBS to standardize the
number of cells used in the assay. As a modification of
the original protocol, all subsequent handling of cells in
1.5 ml sample tubes (Eppendorf, Hamburg, Germany)
was performed in 96-well round-bottom plates (Corning,
NY, USA) instead. To detect parasite-specific immuno-
globulin G (IgG), parasite suspension (2 μl of approx.
5.0 x 107 cells per ml) was added into each well of the
96-well plate resulting in a total volume of 100 μl of test
sera and control samples (each diluted in PBS/3%BSA)
and allowed to bind for 1 h at RT on a plate shaker. After
incubation, the cells were washed thrice with 150 μl of
PBS to remove excess unbound primary antibody. Subse-
quently, pellets were resuspended in 100 μl AlexaFluor
488 goat anti-human IgG (Molecular Probes, Germany),
diluted in PBS/3%BSA, and incubated in the dark for 1
hour. Following three washes with PBS, cells were stored
at 4°C in the dark prior to cytometric analysis.
Antibody dilutions of both primary and secondary
antibodies used in the assay were pre-determined
through checkerboard titration experiments. The com-
bination of antibody dilutions that gave the best separ-
ation between negative and positive fluorescent parasites
was selected and used in subsequent experiments.
Furthermore, different dilutions of three second-step
AlexaFluor-conjugated goat anti-human IgG antibodies
as well as a non-conjugated anti-histidine rich protein 2
(HRP2) monoclonal IgM (used as positive control) were
tested. In addition, the shelf-life of parasite preparations
was estimated by re-assaying at Days 0, 3, 7, and 14,
since measurements from large clinical trials may take
more than one day and it would be preferable to be able
to use one parasite batch for such extended analyses.
Assay controls
Parasites stained i) without primary Ab and ii) with
serum from malaria naïve donors followed by the fluor-
escently labelled secondary antibody were used as nega-
tive controls. Positive control serum came from a pool
of serum from malaria-exposed semi-immune adults
living in Lambaréné, Gabon. As an additional positive
control, infected RBCs were stained for HRP2 with a
mouse monoclonal Ab (55A, anti-PfHRP2; Immunology
Consultants Laboratories, Newberg, USA) at a 20 μg/ml
concentration. Detection was performed using a 1/3,000
dilution of AlexaFluor 633 goat anti-mouse IgM (Invi-
trogen, Germany). Before analysing the cells with a flow
cytometer, fluorescence microscopy was done to verify
the effectiveness of the fluorescence stains and to verify
the cellular localization of Ab-bound parasite proteins.
Flow cytometry data acquisition and analysis
Parasite-infected cells were measured on a Becton
Dickinson FACS Canto II flow cytometer equipped with
the FACSDiva software version 6.1.2 (BD Biosciences,
San Jose, USA) and an attached Carousel loader in high
throughput mode. Relative fluorescence intensity of
each event was analysed using FACSDiva software ver-
sion 6.1.2 (BD Biosciences, San Jose, USA). Ab-reactivity
was expressed as percentage of positive fluorescent cells
(PPFC) and mean fluorescent intensity (MFI). Data
acquisition was stopped after 50,000 events for each
serum sample tested.
Model-based analysis of flow cytometry data
Several model-based algorithms have been developed to
automate the gating process thereby directly addressing
several inherent limitations in gating-based analysis [19].
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Some of these methods, including two popular model-
based approaches, k-means [20] and an implementation
of the Expectation Maximization algorithm (EM) [21] were
tested on two experimental datasets. As part of this work,
the Overlap Subtraction Algorithm (OSA) was developed
and compared with model-based approaches. All described
methods were benchmarked using manual gating as a gold
standard. The OSA is implemented in the programming
language R and is available from the authors.
Design and mode of operation of the overlap
subtraction algorithm
The algorithm effectively mimics manual gating whenever
the gate is set with respect to an internal control. It detects
overlapping areas of two datasets (e.g. between a control
and the measurement of interest) in the two-dimensional
space and sets a gate at the border of the overlap. Cur-
rently, the algorithm is able to process one colour staining,
though it can be easily extended to process multicolour
staining. The algorithm accepts files in the flow cytometry
standard (FCS) 2.0 and 3.0 formats. MFI and PPFC are
computed and reported as output.
With flow cytometry typically a fixed number of cells
(e.g. 50,000) C are measured and analysed for each sam-
ple. Depending on the nature of the experiment, for each
measured cell ci ∈ C a vector of attributes a1. . .an can be
assigned, e.g., colour intensities for different dyes, for-
ward scatter (FSC), side scatter (SSC), etc. Generally,
each cell is represented by a data point in the two-
dimensional space, defined by the attributes a1 and a2.
The algorithm starts by partitioning the whole value
range for each attribute ai of interest in β equidistant inter-
vals, resulting in the vectors A1 and A2 of length β. The
next step is to define two | A1 | x | A2 | matrices T and C
for the test and control sample respectively. Then the
values for Tij and Cij are calculated according to:
Tij ¼ cj j≥A1i∧ cj j < A1iþ1 þ cj j≥A2j∧ cj j < A2jþ1
Cij ¼ cj j≥A1i∧ cj j < A1iþ1 þ cj j≥A2j∧ cj j < A2jþ1 ð1Þ
Each entry in the matrices T and C stores the number of
data points |c| whose values for the attributes a1 and a2 lie
within a certain interval defined by the two vectors A1 and
A2. Next, the percentage of data points coming from the test
sample is determined according to the following formula:
Rij ¼ Tij= Cij þ Tij
  ð2Þ
Following this calculation, positive entries are selected,
i.e. entries in R that exceeds a certain threshold λ. To
Day 0  Day 84  
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Figure 1 Representative overlay showing the anti-plasmodial Ab responses of a semi-immune individual vaccinated with GMZ2.
The best separation between the negative and positive fluorescent cells is obtained when serum was diluted at 1/4,000. Test and control samples
were treated as described in the methods. Note the increase in fluorescence intensity as shown by the shift to the right when parasites were
incubated with serum diluted 1/32,000 (blue curve), 1/16,000 (orange curve), 1/8,000 (light green curve), 1/4,000 (green curve) or the control
(red line) and the overall higher response after vaccination (Day 84).
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Figure 2 Dose–response relationship in pooled serum.
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fluorescence intensity (MFI) and connected squares percentage of
positive fluorescent cells (PPFC).
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achieve a high specificity, λ is set to 0.99 by default,
meaning that 99 percent of the data points that were
counted for a particular entry come from the test sam-
ple. The correct gate is then set by finding the ωth occur-
rence of an entry with:
Zij≤λ ð3Þ
The parameter ω controls the sensitivity of the
method. In practice it is used to fine-tune the gate’s
distance to the negative control. By using low values
of ω the gate is set close to the border of the negative
control sample. Higher values of ω tend to produce
gates that have a bigger gap from the control sample.
After selection of relevant entries, the final gate is
determined by Loess Regression through the selected
coordinates.
Statistical analysis of datasets from different populations
To detect differences in the MFI between groups due to
vaccination, a linear regression model was used. To ac-
count for baseline differences on Day 0, it was included
as covariate in the model (see Formula 4). Raw MFI
measurements were log10 transformed before use in fur-
ther analysis.
MFIday84 ¼ β0þβ1 MFIday0 þ β2  vaccine group ð4Þ
For PPFC measurements, which cannot be assumed to
follow a normal distribution, standard transformations
to achieve normality as proposed by Ahrens et al. [22]
did not work for both datasets. Therefore, log2 fold
changes between Day 0 and Day 84 were calculated.
Between-group differences in the children dataset were
tested by a one-way ANOVA followed by contrast
Figure 3 Dose–response relationship in individual samples from semi-immune donors. A set of 40 paired Day 0 (left panel) and Day 84
(right panel) sera from the same semi-immune population as in Figure 2. Dose-dependent responses can be seen for both the mean
fluorescence intensity (MFI, upper panel) and percentage of positive fluorescent cell (PPFC, lower panel).
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extraction for comparisons of interest. Effects of vaccin-
ation within groups were tested by Student’s t-test.
Between-group comparisons and effects of vaccination
in the adult dataset were tested using a non-parametric
Wilcoxon test because even after transformation or calcu-
lation of ratios the data shows deviations from a normal
distribution. To compare results derived manually as well
as those obtained by automatic gating, Pearson’s correl-
ation coefficients were calculated using log10 transformed
Ab data measured as MFI. For PPFC comparisons Spear-
man’s rank correlation was used. Agreement between the
methods was further evaluated with the Bland-Altman
method [23]. The 95% confidence intervals for the mean
difference are indicated for all Bland-Altman plots. All ana-
lyses were done with R v.2.13.0 [24] and statistical signifi-
cance was defined as a two-sided p<0.05.
Results
Setup of assay parameters
To develop a standardized flow cytometric IFA to assess
the Ab-reactivity to fixed P. falciparum parasites, a pub-
lished fixation protocol [18] was adapted for use in flow
cytometry. The basis for optimization was the best dis-
crimination between positive and negative cells upon
incubation with a serum pool from semi-immune indivi-
duals and preserved integrity and morphology of the
cells. The final fixation and permeabilization conditions
are given in the methods. Titration experiments showed
that the use of semi-immune sera diluted at 1/4,000 fol-
lowed by a 1/3,000 dilution of AlexaFluor 488 conju-
gated goat anti-human IgG best discriminated between
negative and positive fluorescent cells (Figure 1).
Assay validation procedure
Following protocol development the new flow
cytometry-based assay was validated using African semi-
immune serum samples. These sera were selected on the
basis of high anti-GMZ2 Ab-concentrations in ELISA.
To assess concentration-dependent responses in anti-
body levels, a semi-immune serum pool diluted from 1/
1,000 to 1/128,000 was used. Staining was specific (Fig-
ure 2) with only minimal cross-reaction to negative
samples.
In addition, experiments were performed using a set of
40 Day 0 and Day 84 sera from the GMZ2 phase Ib trial
in Gabonese adults serially diluted from 1/4,000 to 1/
32,000. As expected, the PPFC and MFI values were
dependent on the serum concentration (primary anti-
body) used in the assay and showed a consistent and
obvious dose-dependent response relation on the differ-
ent time points (Figure 3).
Application of model-based algorithms in flow cytometry
data analysis
Model-based gating algorithms were tested on two
datasets. Of these, only two methods (k-means and the
EM algorithm) tend to produce results that were compar-
able to those obtained by manual gating. They were
selected and their performance was further evaluated in
comparison to the manual gating strategy. Considering the
MFI, results from the two methods do significantly corre-
late (p<0.001) with those obtained manually in both data-
sets. In contrast, k-means produced non-significant results
for PPFC on Day 0 and 84 in the population of Gabonese
adults when compared to manual gating. In the pediatric
Table 1 Correlation of the four strategies employed for gating raw flow cytometry data
Manual gating
Gabonese adults (n = 37)a MFI day 0 MFI day 84 PPFC day 0 PPFC day 84
k-means r = 0.95 r = 0.89 ρ = 0.04§ ρ = 0.14§
r2 = 0.91 r2 = 0.79
EM* r = 0.92 r = 0.89 ρ = 0.89 ρ = 0.94
r2 = 0.85 r2 = 0.80
Overlap subtraction r = 0.99 r = 0.98 ρ = 0.99 ρ = 0.99
r2 = 0.99 r2 = 0.96
Gabonese children (n = 28)b MFI day 0 MFI day 84 PPFC day 0 PPFC day 84
k-means r = 0.71 r = 0.76 ρ = −0.93 ρ = −0.88
r2 = 0.51 r2 = 0.59
EM* r = 0.61 r = 0.64 ρ = 0.78 ρ = 0.81
r2 = 0.38 r2 = 0.41
Overlap subtraction r = 0.79 r = 0.83 ρ = 0.94 ρ = 0.96
r2 = 0.62 r2 = 0.69
*Expectation Maximization. r = Pearson’s correlation coefficient. r2 = Coefficient of determination. ρ = Spearman correlation coefficient. Ab (IgG) responses are
expressed as mean fluorescence intensity (MFI) and percentage of positive fluorescent cell (PPFC). Correlations for MFI were calculated using log10 transformed
data. aData excluded for 3 participants due to problems with data acquisition and inability of some algorithms to set an appropriate gate. bTwo participants have
been excluded from analysis for the same reasons as above. All p-values are significant (p < 0.001) except for those marked with §.
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dataset, k-means-based results for PPFC measurements
were even negatively correlated with those derived by
manual gating (ρ=-0.93 on Day 0, ρ=-0.89 on Day 84, both
p<0.001) (Table 1). Figures 4 and 5 show correlation
matrices from Gabonese adults and children comparing
the different analytical approaches using Day 0 PPFC mea-
surements. Despite the significant correlation in most
comparisons, Bland-Altman analyses show considerable
lack of agreement between k-means, EM and manual
gating for both, MFI and PPFC (Table 2). In both datasets
k-means tends to under-estimate whereas EM over-
estimates the MFI using results from the manual gating as
reference. With regards to the PPFC among the children
population, k-means over-estimates it by 40% and 34%
on Day 0 and Day 84 respectively when compared to
the manual gating. The poor performance of these
methods on the datasets therefore motivated the
development of a new method for data-driven gating.
Since the different statistical approaches were not well-
suited for the data, an algorithmic approach (OSA) was
tested. In general, the algorithm produced results, which
compared well (p<0.0001) to manually gated data
Figure 4 Correlation matrix of results from different flow cytometry data analysis methods: adults. PPFC measurements for Day 84 from
Gabonese adults. The diagonal separates scatterplots (lower part) and the respective correlation coefficients (upper part).
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(Table 1). In terms of MFI and PPFC for the different
time points, the correlation appeared to be stronger for
the adults (r ≥ 0.98) than for the children (r ≥ 0.79). In
contrast to the other methods, OSA shows a high
agreement with the results obtained from manual gating
(Table 2). The expected absolute error for the PPFC in
the semi-immune adults population is 30 and 60 times
lower than for EM and k-means, respectively (Table 2).
Figure 6 shows representative Bland–Altman plots with
95% limits of agreement (LOA). From all methods
tested, OSA shows the smallest 95% LOA in terms of
PPFC and MFI (Table 2).
Application of the cytometric IFA on sera from
vaccinated subjects
The new method was applied to datasets from two
GMZ2 phase Ib trials to detect possible effects of vac-
cination on Ab response. Each dataset consists of
paired serum samples taken on Day 0 pre- and Day 84
post-vaccination. In total, 70 samples were analysed, 40
from semi-immune adults [8] and 30 from pre-school
children [7], both from Gabon. Figure 7 illustrates the
log2 fold changes in PPFC between Day 84 and Day 0
(baseline) responses of the different vaccine groups.
Among children, most volunteers in the two subgroups
Expectation
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Figure 5 Correlation matrix of results from different flow cytometry data analysis methods: children. PPFC measurements for Day 84
from Gabonese children. The diagonal separates scatterplots (lower part) and the respective correlation coefficients (upper part).
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vaccinated with GMZ2 had a higher response on Day
84 (63% and 90% who received 30 μg and 100 μg
GMZ2, respectively). Out of all volunteers vaccinated
with GMZ2, only those who received 100 μg GMZ2
showed a significant increase (p=0.003) in their Ab
reactivity (1.33-fold, 95% CI: 1.15, 1.55), while no sig-
nificant increase was observed in the 30 μg group
(1.01-fold, 95% CI: 0.81, 1.27). Interestingly, 33% of all
participants in the rabies-vaccinated group had also a
higher response on Day 84. However, the remaining
six showed no or minimal increase in reactivity on
Day 84. As a consequence, no significant increase in
vaccine response was detected on Day 84 (1.09-fold,
95% CI: 0.94, 1.28). In contrast to the pre-school chil-
dren, no significant treatment effect on Day 84 was
detectable neither in the 100 μg GMZ2 (0.83-fold, 95%
CI: 0.71, 0.99) nor in the rabies control group (1.08-
fold, 95% CI: 0.97, 1.21) of the adult volunteers. In
addition, no differences between the vaccine groups
could be detected in both datasets. Interestingly, by
applying a linear regression model (Table 3) to the
log10 transformed MFI values, which adjusts for the
Ab reactivity on Day 0 (baseline), significantly higher
vaccine responses (p=0.03) were detected in the 100
μg GMZ2 group compared to the rabies group. In the
pre-school children population no significant between-
groups differences were detected.
Discussion
A well-studied reaction of the immune system to mal-
aria or vaccination with malaria vaccine candidates
is the induction of antigen-specific antibodies [25].
Implementation of assays that adequately detect levels of
antibodies induced by natural exposure or vaccination is
critical for monitoring immunogenicity. In this respect,
flow cytometric-based IFA techniques similar to the
approach described here have extensively been employed
to assess total IgG antibodies in the sera of humans
infected with protozoan parasites different from Plasmo-
dium [26-32]. With human malaria, some studies have
adapted related techniques - mainly to analyse responses
against plasmodial variant surface antigen [12,33-36],
which may have a role in parasite virulence or be used
as vaccine candidates.
Here, a novel approach for immunofluorescence
assays, which incorporates flow cytometry and offers
a rapid and reliable method of measuring total anti-
plasmodial Ab in human serum, is presented. In
contrast to conventional methods which utilize re-
combinant or synthetic peptides as antigen to assess
Ab responses [9], the improved workflow has several
advantages: i) Plasmodium parasites can be routinely
maintained in continuous in vitro cultures to produce
enough material for medium- to high-throughput
assays; ii) the use of whole-cell preparations of P. fal-
ciparum may preserve the target protein’s antigenic
properties better compared to soluble antigens [3],
which could be essential for an effective anti-parasitic
reaction to occur; and iii) the protein of interest is pre-
sented in its native context. Since fixed parasites
remained intact and stable for more than 2 weeks when
stored at 4°C, it is possible to analyse large sample
numbers over an extended period of time. Further-
more, data acquisition using a flow cytometer equipped
with a carousel or plate loader in high-throughput
mode ensures rapid and consistent analysis of samples
Table 2 Bland-Altman analyses of the different data gating strategies
Manual gating
Gabonese adults (n = 37)a MFI day 0 MFI day 84 PPFC day 0 PPFC day 84
k-means 611 600.9 −0.04 −0.06
(464.3, 757.7) (350.5, 851.3) (−0.09, 0.005) (−0.12, -0.005)
Expectation −388.3 −328.7 0.02 0.01
Maximization (−600.2, -176.4) (−604.8, -52.7) (0.004, 0.04) (−0.003, 0.03)
Overlap subtraction −124.2 −98.1 0.006 −0.004
(−160.3, -88.2) (−143.4, -52.7) (0.003, 0.009) (−0.02, 0.001)
Gabonese children (n = 28)b MFI day 0 MFI day 84 PPFC day 0 PPFC day 84
k-means 198.6 205.8 −0.4 −0.34
(166.7, 230.6) (176.8, 234.8) (−0.49, -0.31) (−0.42, -0.27)
Expectation −208.9 −171.7 0.09 0.06
Maximization (−290.4, -127.3) (−214.5, -128.9) (0.03, 0.14) (0.05, 0.08)
Overlap subtraction 39.8 56.2 −0.04 −0.05
(25.1, 54.5) (43.6, 68.9) (−0.03, -0.05) (−0.06, -0.03)
Ab reactivity is expressed as mean fluorescence intensity (MFI) and percentage of positive fluorescent cell (PPFC). Data is given as mean differences of MFI
and PPFC values (lower and upper 95% confidence interval) between the different approaches. aData excluded for 3 participants due to problems with data
acquisition and inability of some algorithms to set an appropriate gate. bTwo participants have been excluded from analysis for the same reasons as above.
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Figure 6 Representative Bland-Altman plots obtained by comparing different analytical approaches. The x-axis shows the mean of
both computationally and manually derived estimates for the PPFC and the y-axis the difference between them. The inner solid line represents
the mean difference for PPFC values while the outer dotted lines denote the lower and upper 95% limits of agreement between the
different strategies.
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thereby reducing sample processing time and handling
variations. This greatly improves the assay reliability
when compared to the microscopic IFA technique,
where the effort is limited by the microscopist’s ex-
perience and speed and where substantial variation
among microscopists is common. The level of
standardization and throughput that is possible using
fully automated synthetic or recombinant peptides
cannot be attained with such an approach.
The conventional method of manual gating of flow
cytometry data is often investigator-dependent and diffi-
cult to standardize. To overcome these shortcomings
several statistical methods have been proposed in the lit-
erature. After applying them to two study datasets, even
the best performing ones (k-means and EM) showed
high error rates when compared to expert manual
gating. This disadvantage was remedied by the develop-
ment of a new algorithm (OSA), which, in contrast to
model-based methods, does not make any assumption
on the data distribution and mimics manual gating strat-
egies. OSA-derived results correlate well with those
derived by manual gating. As a data-driven algorithm,
OSA may not perform equally well in other experimen-
tal setups as it depends heavily on the data structure.
The whole workflow (cytometric IFA plus OSA) was
validated using samples from two vaccine studies in mal-
aria exposed adults and children who profoundly differ
in their baseline anti-plasmodial immunity and showed
a significant increase in specific Ab-reactivity against
the GMZ2 vaccine after vaccination [7,8]. By applying
the workflow, a moderate but significant increase in
vaccine-induced Abs response was observed based on
the PPFC, one month after a full immunization schedule
(Day 84) in a subgroup of children who received the
highest dose of GMZ2 (100 μg). Meanwhile, the effect
induced by a lower dose of the vaccine (GMZ2 30 μg)
was small and no significant treatment effect was detect-
able with this approach. A larger sample size may be
required to detect a significant effect in this subgroup.
In contrast to GMZ2-specific ELISA, which distin-
guishes GMZ2- from control-vaccinated children con-
sistently, cytometric IFA results represent the integrated
reactivity against all accessible parasite antigens after cell
permeabilization. This decreases the ability to detect a
specific signal but adds information about the size of the
effect in the context of naturally acquired immunity and
consequently complements antigen-specific methods.
Based on the PPFC outcome measure, no treatment
effect was observed in semi-immune adults immunized
with 100 μg GMZ2 (Figure 7). In contrast, a signifi-
cant vaccination effect was detected between the two
subgroups in the adult dataset when considering the
MFI (Table 3). From the statistical point of view, a possible
explanation for the contrasting observations in the two
outcome measures (MFI and PPFC) may relate to the fact
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Figure 7 Changes in Ab levels of Gabonese adults and children following immunization with GMZ2. Data is expressed as log2 fold
change in PPFC between Day 0 and Day 84. P-values were obtained by a one-way ANOVA and the Wilcoxon test for the children and adults’
data respectively.
Table 3 Fold-changes in Ab reactivity after GMZ2
immunization of Gabonese adults and children
Study populations Mean (95% CI) P-value Comparison
Gabonese adults 1.23 (1.02, 1.48) 0.03 GMZ2 100 μg/Rabies
Gabonese children 1.04 (0.92, 1.17) 0.52 GMZ2 30 μg/Rabies
1.04 (0.93, 1.16) 0.48 GMZ2 100 μg/Rabies
1.0 (0.89, 1.13) 0.98 GMZ2 30 μg/100μg
Ab reactivity is presented as mean fluorescent intensity (MFI). Data is shown
as mean fold changes of the different comparisons (95% confidence interval).
P-values for MFI comparisons derived by linear regression model.
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that outlying data points have a greater influence on MFI
than PPFC. Consequently, PPFC is the more conservative
measure and should be preferred in case of discordant
results when no mechanistic explanation is present. In the
present study, two different populations, which largely dif-
fer in their response pattern after vaccination were investi-
gated. Children with no or very little immunity develop
anti-plasmodial antibodies upon vaccination (increase
in PPFC), whereas in semi-immune adults a vaccine-
mediated boost of pre-existing anti-parasitic immune
response that translates into improved parasite recogni-
tion (increased MFI) is expected. Therefore, the results
are in line with the mechanistic concept of vaccination in
naïve and pre-exposed populations, respectively.
The relatively high pre-vaccination antibody levels
with specificities to different malaria parasite antigens
reported in the adults population [8] contribute much to
the large variation in the data. Therefore it is not surpris-
ing that a response to a single antigen is difficult to de-
tect. Nevertheless, results from this investigation
illustrate that a vaccine-induced increase in Ab- binding
to fixed Plasmodium parasites is detectable by this
methodology, demonstrating their potential functional
properties [34]. However, the assay may need further
adaptation for its use in subjects with no previous expos-
ure to malaria and low immune responses as was
observed in pilot experiments. IgG subclass-specific Ab
responses, especially the cytophilic antibodies known to
be associated with reduced risk of malaria [37,38], have
not been addressed in the present study but can be inte-
grated rather easily.
In summary, a new flow cytometry-based immunofluor-
escence assay is presented. It is a cheap, reliable and rapid
method to detect and quantify anti-plasmodial antibodies
in human sera and may be of value in malaria research. As
a next step this workflow will be applied to samples from
clinical phase II/III trials of malaria vaccine candidates to
characterize Ab-mediated immune responses and identify
correlates of vaccine-induced protection against malaria.
The non-biased data-driven computational analysis tool
(OSA) integrated in this methodology will be provided
under a general public license to the scientific community.
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Abstract
Background: The malaria vaccine RTS,S induces antibodies against the Plasmodium falciparum circumsporozoite
protein (CSP) and the concentration of Immunoglobulin G (IgG) against the repeat region of CSP following vaccination
is associated with protection from P. falciparum malaria. So far, only the quantity of anti-CSP IgG has been measured
and used to predict vaccination success, although quality (measured as avidity) of the antigen-antibody interaction shall
be important since only a few sporozoites circulate for a short time after an infectious mosquito bite, likely requiring fast
and strong binding.
Methods: Quantity and avidity of anti-CSP IgG in African infants who received RTS,S/AS01E in a 0-1-2-month or a
0-1-7-month schedule in a phase 2 clinical trial were measured by enzyme-linked immunosorbent assay. Antibody
avidity was defined as the proportion of IgG able to bind in the presence of a chaotropic agent (avidity index). The
effect of CSP-specific IgG concentration and avidity on protective efficacy was modelled using Cox
proportional hazards.
Results: After the third dose, quantity and avidity were similar between the two vaccination schedules. IgG avidity after
the last vaccine injection was not associated with protection, whereas the change in avidity following second and third
RTS,S/AS01E injection was associated with a 54% risk reduction of getting malaria (hazard ratio: 0.46; 95% confidence
interval (CI): 0.22-0.99) in those participants with a change in avidity above the median. The change in anti-CSP
IgG concentration following second and third injection was associated with a 77% risk reduction of getting malaria
(hazard ratio: 0.23, 95% CI: 0.11-0.51).
Conclusions: Change in IgG response between vaccine doses merits further evaluation as a surrogate marker for
RTS,S efficacy.
Trial registration: ClinicalTrials.gov Identifier NCT00436007.
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Background
Malaria has an enormous public health impact and new
preventive interventions are urgently needed. After more
than 100 years of research on malaria vaccines, RTS,S
was the first pre-erythrocytic vaccine candidate that en-
tered phase III clinical development [1-3]. RTS,S con-
tains hepatitis B surface antigen (HBsAg) together with a
fusion protein of HBsAg and a carboxy-terminal frag-
ment of Plasmodium falciparum circumsporozoite pro-
tein (CSP), co-expressed in yeast and formulated with a
proprietary adjuvant (AS01). The exact mechanism of
RTS,S-mediated protection is not known, although Im-
munoglobulin G antibodies (IgG) against the CSP repeat
region are likely to play an important role since the con-
centration of anti-CSP IgG partly explains protection in
most studies that assessed efficacy of RTS,S in African
children [4-6]. In addition, passive transfer of anti-CSP
IgG can protect animals from subsequent challenge
[7,8]. Besides concentration, many other properties de-
termine antibody function. Among them are availability
of effector molecules, post-translational modification,
isotype, subclass, affinity and avidity of antibodies. It is
difficult to measure all these characteristics in one sam-
ple, particularly in the small sample volumes obtained
during clinical trials in infants. Affinity, defined as the
strength of interaction between an epitope and an anti-
body binding site, would be a particularly interesting
variable to measure in the context of anti-CSP IgG-
mediated immunity, since the time of interaction with
the parasite is short (less than 30 minutes [9]), sporozo-
ites are strongly diluted and few. In fact, only one suc-
cessful hepatocyte infection is sufficient to initiate and
maintain blood stage infection. Studies in mice have
shown that high antibody affinity against a synthetic
CSP immunogen is positively associated with protection
[8,10] and most studies in humans indicate that anti-
CSP IgG concentration explains only parts of the
vaccine-mediated protection. Increase in antibody affin-
ity after repeated antigen exposure is the result of affin-
ity maturation due to somatic hypermutation. The rate
and extent of maturation may be influenced by several
factors, including nature, route and dose of the antigen,
adjuvants and carriers as well as the immunization
schedule. In the present study antibody avidity was mea-
sured. It is a representation of the strength of interaction
between antibodies and antigens in a complex and be-
sides antibody affinity, valences of antibodies and anti-
gens as well as structural features of the complex are
important determinants of avidity. For CSP, it has been
shown that the use of some adjuvants can increase the
avidity of anti-CSP IgG after vaccination of human vol-
unteers [11]. In this study IgG avidity against the repeat
region of CSP was measured after the second and third
injection of RTS,S/AS01E in infants that received the
vaccine as part of a phase IIb clinical trial to assess safety
and efficacy of RTS,S/AS01E in the age-group targeted by
the expanded programme on immunization (EPI) [5,12].
Methods
Clinical trial
The objective of the study was to explore the effect of
anti-CSP IgG avidity on RTS,S vaccine efficacy in naturally
exposed infants. Details of the clinical trial have been pub-
lished previously [5,12]. Briefly, safety and efficacy of RTS,
S/AS01E when given through the EPI was assessed in 511
children from Gabon, Ghana and Tanzania. Participants
were randomly assigned to one of three intervention arms:
1) RTS,S/AS01E as three injections, one month apart (0, 1,
2 months schedule [012]; n = 170), 2) RTS,S/AS01E ex-
tended schedule (0, 1, 7 months schedule [017]; n = 170)
or 3) control (EPI vaccines alone; n = 171). Malaria was
defined as parasitaemia >500 parasites per μl and an axil-
lary temperature >37°C. The efficacy of RTS,S against first
malaria episodes, detected by passive case detection, was
equivalent in the two schedules one year after the third
injection. The study followed Good Clinical Practice
guidelines, the Declaration of Helsinki (4th revision) and
received approval from the appropriate local and national
ethics committees of each site. In addition, ethical re-
view by the ethics committees of the London School of
Hygiene and Tropical Medicine Ethic Committee, the
Swiss Tropical Institute Committee and the Western
Institutional Review Board was sought. The trial is
registered with ClinicalTrials.gov (NCT00436007).
Antibody measurements
Antibodies against CSP were measured by evaluating
IgG responses against the CSP-repeat region, using a
validated enzyme-linked immunosorbent assay (ELISA)
with R32LR as the coating antigen [13]. An anti-CSP
IgG titre of 0.5 ELISA units per millilitre (EU/mL) or
greater was considered to be positive. For measurements
of avidity of IgG against the repeat region of CSP,
samples were evaluated as described [13], but in two dif-
ferent plates; one treated with a chaotropic agent and
one untreated plate. As chaotropic agent a 1 M solution
of ammonium thiocyanate (NH4SCN) was added in the
treatment plate while 0.05% Tween-20 in PBS was added
in the untreated plate and both CSP ELISA plates were
further washed and developed as described [13]. The
avidity index (AI) was calculated as the ratio of the con-
centration of anti-CSP IgG (EU/ml) that remained
bound to the coated antigen after treatment with
NH4SCN, divided by the concentration of IgG (EU/ml)
that remained bound to the coated antigen in the un-
treated plate. Anti-CSP IgG quantification and avidity
were measured at the Center for Vaccinology, Ghent
University Hospital, Belgium.
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For statistical modelling the logarithm of anti-CSP IgG
concentration was used since previous data showed that
log-transformation results in a better fit to the normal
distribution. AI was analysed in the two RTS,S-vacci-
nated arms and after the second and third vaccination.
Since the majority of infants before vaccination and
those receiving control vaccine do not have measurable
anti-CSP IgG, AI cannot be calculated. Delta AI (dAI)
was defined as the difference in AI between the second
and third vaccination. Similarly, delta CSP (dCSP) was
defined as the difference in anti-CSP IgG concentration
between the second and third vaccination.
Statistics
Analysis of the effect of IgG avidity on protective effi-
cacy was exploratory and not detailed in the statistical
analysis plan of the original study. IgG responses be-
tween the groups were analysed by descriptive statistics
and represented as boxplots together with the individual
measurements. The effect of anti-CSP IgG concentration
and AI on risk of malaria was calculated using the
according-to-protocol (ATP) dataset with a Cox propor-
tional hazards model in R v2.15.2. For statistical model-
ling antibody concentrations were log-transformed. To
calculate the effect of dAI and dCSP on the occurrence
of malaria episodes with a Cox proportional hazards
model, values were dichotomized on the median dAI or
dCSP and labelled as ‘high’ and ‘low’, respectively. All
models included the covariates schedule and site. If ap-
propriate, other covariates were added as reported in the
results section. A p-value below 0.05 was considered sig-
nificant and 95% confidence intervals (95% CI) are given
where appropriate.
Results
After screening 605 participants, 170 received RTS,S in
the standard (012) and 170 in the extended (017)
schedule, as depicted on the CONSORT flowchart of
the primary study (Figure 1). Samples from 315 (300
ATP) participants were available for immunological
analysis (012: n = 154 [148]; 017: n = 161 [152]). Paired
immunological samples to calculate dAI were available
from 187 (179 ATP) participants (012: n = 103 [100];
017: n = 84 [79]).
As reported earlier [5], high anti-CSP IgG titres after
three vaccine injections were associated with a reduc-
tion in subsequent incidence of clinical malaria: the
hazard ratio of a ten-fold increase in anti-CSP IgG was
0.52 (95% CI: 0.34-0.81), which corresponds to a 48%
risk reduction.
Absolute AI after two (012: 35.9, 017: 34.9; t-test p = 0.57)
and three (012: 41.2, 017: 39.3; t-test p = 0.22) RTS,S injec-
tions were similar between the two vaccination schedules
(Figure 2). As expected, an increase in AI between the
second and third vaccination was present (Figure 3). In-
crease in delta AI (dAI) was slightly, albeit not statistically
significant, higher in the 017 (7.1) group compared to the
012 (4.2) group (delta: 3.0; 95% CI: −0.3-6.1; t-test p = 0.08).
To explore the effect of AI, dAI and dCSP on malaria
risk, three Cox proportional hazard models were defined
and tested. AI after the third injection, corrected for site,
schedule and anti-CSP IgG concentration, did not ex-
plain a significant reduction in risk of clinical malaria
(Model 1; hazard ratio: 0.99, 95% CI: 0.97-1.02). Partici-
pants were then divided on the median in dCSP and dAI
‘high’ and ‘low’ responders and included as categorical
variable in the model. Classification as ‘high-dCSP’ was
associated with a significant risk reduction (77%) com-
pared to the ‘low dCSP’ group in a model corrected for
site and schedule (Model 2; hazard ratio: 0.23, 95% CI:
0.11-0.51). When dAI, corrected for site, schedule and
dCSP was analysed, the hazard ratio between high and
low responders separated by the median, was 0.46
(Model 3; 95% CI: 0.22-0.99; Wald test p = 0.049), hence
classification as ‘high dAI’ group member is associated
with a 54% risk reduction (Figure 4).
Discussion
The complex interplay of vaccine-primed immune medi-
ators that define a successful response upon pathogen
encounter is not well understood. Cellular and humoral
components have important roles, although in various
compositions, depending on the pathogen and the host.
Antibodies are the prototypic vaccine-induced immune
mediators and play an important role in anti-malarial
immunity during the pre-erythrocytic [8,10] as well as
the erythrocytic stage [14] of the disease, as shown by
passive transfer experiments in mice and man. The sheer
concentration of antigen-specific antibodies is normally
used to measure immunization success and serves as a
surrogate to estimate protective efficacy. The clinical de-
velopment of RTS,S is a unique opportunity to investi-
gate the effect of further variables such as antibody
avidity, isotype or subclass on vaccine efficacy, since
clinical (true) efficacy is known [5], being 57% (95% CI:
33–73) with the 012 schedule and 32% (95% CI: 16–45)
following the 017 schedule.
Here, anti-CSP IgG avidity was measured to assess if it
predicts vaccine efficacy in a phase II clinical trial of
RTS,S independent of anti-CSP IgG concentration
[5,12]. Regardless of the vaccination scheme and site,
avidity did not improve prediction over anti-CSP IgG
concentration alone. This may mean that: i) the assay is
not sensitive enough to reflect avidity; ii) collinearity be-
tween antibody concentration and avidity blurs the effect
of avidity; or, iii) that avidity is not an important deter-
minant of vaccine efficacy. In this study IgG concentra-
tion and avidity was measured after the second and third
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vaccine injection. This approach is valid to assess if the
immune system reacted to vaccination successfully.
Since kinetics of IgG vary over time and the study was
performed under natural exposure to malaria parasites,
the time of encounter with the parasite becomes an im-
portant variable. This is in contrast to controlled human
malaria infection (CHMI) studies, where the time of in-
fection is defined. Hypothetically, the difference in IgG
concentration (and avidity) between second and third
vaccination could be a better predictor of effective
antibody-mediated protection than concentration after
the third vaccine injection, because it better reflects the
Figure 1 CONSORT study flow chart.
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further evolution of antibody responses until next para-
site encounter. The present data argue for the use of this
approach since it was shown that a high dCSP predicts
protective efficacy and dAI explains part of the protec-
tion in the RTS,S vaccinated children (Model 3). How
AI evolves over time and if it is a useful predictor of
vaccine efficacy remains to be validated with further, in-
dependent and confirmatory studies.
Nevertheless, this observation adds a new component
to the search of correlates of protection and the under-
standing of the immune responses elicited by pre-
erythrocytic malaria vaccine candidates such as RTS,S.
Since adjuvants also have a profound effect on the speed
of avidity maturation [11], the effect of avidity on vac-
cine efficacy could even be analysed with interventional
studies that assess the effect of timing between immuni-
zations (as in this study) and different adjuvants on pro-
tective efficacy while direct measures of maturation of
the immune system such as single-cell based sequencing
of IgG genes of anti-CSP memory B-cells [15,16] are
performed. This may be particularly interesting for anti-
gens such as CSP that are not highly immunogenic per
se, because highly immunogenic antigens often induce
antibodies with strong avidity over a short period of time
and a threshold antibody concentration is appropriate to
predict their efficacy [17]. Other studies in the develop-
ment of RTS,S (e.g., challenge experiments [18] and the
recently completed phase III trial [1-3]) will certainly
provide additional information and may establish the
measurement of avidity as one biomarker for vaccine effi-
cacy. Additionally, such knowledge may guide the design
of next generation vaccines and administration schemes.
Conclusions
So far, the most robust correlate of protection for the mal-
aria vaccine candidate RTS,S is anti-circumsporozoite
(CSP) IgG concentration following immunization. Pre-
clinical data and theoretical considerations suggest that
avidity may have an additional impact on protective
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Figure 4 Kaplan Meier plot of malaria episodes over time in
participants classified as having high (black) or low (grey) dAI.
Figure 2 Box-plot and single measurements of absolute AI at
second and third vaccination using two vaccination schedules
(012 or 017).
Figure 3 Box-plot and single measurements of difference in AI
(dAI) between second and third vaccination using two
vaccination schedules (012 or 017). Note that for the analysis of
dAI only paired samples were used (n = 179).
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efficacy. It is shown that an increase in anti-CSP IgG con-
centration and avidity between second and third vaccine
injection is associated with a strong risk-reduction for
malaria after immunization. This finding shall influence
the way of analysis of immunological correlates of protec-
tion since using change in antibody concentration and
avidity rather than single measurements enables improved
modelling of immune-effector function at the time of
pathogen encounter and hence more powerful prediction
of vaccine efficacy.
Consent
Written informed consent was obtained from each
child’s parent(s). Illiterate parents were informed about
the study in the presence of an impartial and literate wit-
ness and informed consent was documented by thumb-
print of the parent and signature of the witness.
Abbreviations
AI: Avidity index; dAI: delta AI; CSP: Plasmodium falciparum circumsporozoite
protein; dCSP: Delta CSP; ATP: according to protocol; IgG: Immunoglobulin G.
Competing interests
This study was funded by PATH-MVI and GlaxoSmithKline Biologicals SA. GM
and MT report receiving funding for study-related travels. MT reports receiving
financial compensation for activities outside the submitted work for board
membership of the Optimus Foundation and the Novartis Institute for Tropical
Diseases, having grants pending from both PATH-MVI and the Bill and Melinda
Gates Foundation, and receiving travel reimbursements from PATH-MVI and
Sanaria Corp. JV, EJ, ML, and PC are employees of the GlaxoSmithKline group of
companies. JV, EJ and ML receive GlaxoSmithKline stock and/or options. CFO is
an employee of PATH-MVI. Other authors report no conflicts of interest other
than study funding.
Authors’ contributions
AA and BM drafted the manuscript and performed the statistical analysis. BL,
STA, KPA, SO-A, GM, MM, and NS collected the data and performed analyses.
MT, SA, JV, EJ, ML, PC, CFO, and PGK conceived and supervised the study. All
authors contributed to writing and review of the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
The authors thank the participants and their parents, the community
members and the Chiefs in the traditional areas, and the management and
staff of the local collaborating institutions (the Kintampo Municipal Hospital,
Ghana Health Service, and the Kintampo North and South Health Directorates
in Kintampo). We also thank Jarno Jansen (Keyrus Biopharma, on behalf of GSK
Vaccines) for publication management and editorial assistance. The Deutsche
Forschungsgemeinschaft and the Open Access Publishing Fund of the
University of Tübingen supported publishing this manuscript under a Creative
Commons Attribution License.
Author details
1Eberhard Karls Universität Tübingen, Institut für Tropenmedizin, Wilhelmstraße
27, 72074 Tübingen, Germany. 2Centre de Recherches Médicales de Lambaréné
(CERMEL), BP118 Lambaréné, Gabon. 3Kintampo Health Research Centre, PO
Box 200, Kintampo, Ghana. 4Faculty of Infectious and Tropical Diseases, London
School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.
5Bagamoyo Research and Training Centre of Ifakara Health Institute, Bagamoyo,
360 Kiko Avenue, Mikocheni, PO Box 78373, Dar es Salaam, Tanzania.
6Swiss Tropical and Public Health Institute, Basel, Switzerland. 7GlaxoSmithKline
Biologicals, Rixensart, Belgium. 8PATH Malaria Vaccine Initiative, 455
Massachusetts Avenue NW, Suite 1000, Washington, DC 20001, USA.
Received: 9 October 2014 Accepted: 2 February 2015
References
1. Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Methogo BGNO, Kabwende
AL, et al. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N
Engl J Med. 2012;367:2284–95.
2. Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP,
Conzelmann C, et al. First results of phase 3 trial of RTS, S/AS01 malaria
vaccine in African children. N Engl J Med. 2011;365:1863–75.
3. RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S/AS01 malaria
vaccine during 18 months after vaccination: a phase 3 randomized,
controlled trial in children and young infants at 11 African sites. PLoS Med.
2014;11:e1001685.
4. Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, Msham S, et al.
Efficacy of RTS, S/AS01E malaria vaccine and exploratory analysis on
anti-circumsporozoite antibody titres and protection in children aged
5–17 months in Kenya and Tanzania: a randomised controlled trial. Lancet
Infect Dis. 2011;11:102–9.
5. Asante KP, Abdulla S, Agnandji S, Lyimo J, Vekemans J, Soulanoudjingar S, et al.
Safety and efficacy of the RTS, S/AS01E candidate malaria vaccine given with
expanded-programme-on-immunisation vaccines: 19 month follow-up of a
randomised, open-label, phase 2 trial. Lancet Infect Dis. 2011;11:741–9.
6. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, Sacarlal J, et al.
Safety of the RTS, S/AS02D candidate malaria vaccine in infants living in a
highly endemic area of Mozambique: a double blind randomised controlled
phase I/IIb trial. Lancet. 2007;370:1543–51.
7. Egan JE, Weber JL, Ballou WR, Hollingdale MR, Majarian WR, Gordon DM,
et al. Efficacy of murine malaria sporozoite vaccines: implications for human
vaccine development. Science. 1987;236:453–6.
8. Porter MD, Nicki J, Pool CD, Debot M, Illam RM, Brando C, et al. Transgenic
parasites stably expressing full-length Plasmodium falciparum circumsporozoite
protein as a model for vaccine down-selection in mice using sterile protection
as an endpoint. Clin Vaccine Immunol. 2013;20:803–10.
9. Fairley H. Chemotherapeutic suppression and prophylaxis in malaria. Trans R
Soc Trop Med Hyg. 1945;38:311–55.
10. Reed RC, Louis-Wileman V, Wells RL, Verheul AF, Hunter RL, Lal AA.
Re-investigation of the circumsporozoite protein-based induction of sterile
immunity against Plasmodium berghei infection. Vaccine. 1996;14:828–36.
11. Rickman LS, Gordon DM, Wistar Jr R, Krzych U, Gross M, Hollingdale MR, et al.
Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl
lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet.
1991;337:998–1001.
12. Agnandji ST, Asante KP, Lyimo J, Vekemans J, Soulanoudjingar SS, Owusu R,
et al. Evaluation of the safety and immunogenicity of the RTS, S/AS01E
malaria candidate vaccine when integrated in the expanded program of
immunization. J Infect Dis. 2010;202:1076–87.
13. Clement F, Dewar V, Van Braeckel E, Desombere I, Dewerchin M, Swysen C, et al.
Validation of an enzyme-linked immunosorbent assay for the quantification of
human IgG directed against the repeat region of the circumsporozoite protein
of the parasite Plasmodium falciparum. Malar J. 2012;11:384.
14. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H,
Chantavanich P, et al. Parasitologic and clinical human response to
immunoglobulin administration in falciparum malaria. Am J Trop Med
Hyg. 1991;45:297–308.
15. Busse CE, Czogiel I, Braun P, Arndt PF, Wardemann H. Single-cell based
high-throughput sequencing of full-length immunoglobulin heavy and light
chain genes. Eur J Immunol. 2014;44:597–603.
16. Muellenbeck MF, Ueberheide B, Amulic B, Epp A, Fenyo D, Busse CE, et al.
Atypical and classical memory B cells produce Plasmodium falciparum
neutralizing antibodies. J Exp Med. 2013;210:389–99.
17. Bachmann MF, Kalinke U, Althage A, Freer G, Burkhart C, Roost H, et al. The
role of antibody concentration and avidity in antiviral protection. Science.
1997;276:2024–7.
18. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, et al. A
preliminary evaluation of a recombinant circumsporozoite protein vaccine
against Plasmodium falciparum malaria. RTS, S Malaria Vaccine Evaluation
Group. N Engl J Med. 1997;336:86–91.
Ajua et al. Malaria Journal  (2015) 14:72 Page 6 of 6
